id|number|supplement_number|device_name|generic_name|date_received|decision_date|curated|genetic|description|companion_diagnostic_device_id|type_id
1|P140020|S020|BRACAnalysis CDx|cancer-related germline gene mutation detection system|2019-12-06 00:00:00|2020-05-19 00:00:00|false|true|Approval to expand the intended use of BRACAnalysisÂ® CDx to include a companion diagnostic indication for BRCA1/2 mutations in patients with metastatic castration resistant prostate cancer who may benefit from treatment with LynparzaÂ® (olaparib).|1|1
2|P140020|null|BRACANALYSIS CDX|cancer-related germline gene mutation detection system|2014-09-24 00:00:00|2014-12-19 00:00:00|false|true|APPROVAL FOR THE BRACANALYSIS CDX. THIS DEVICE IS INDICATED AS FOLLOWS: BRACANALYSIS CDX IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION AND CLASSIFICATION OF VARIANTS IN THE PROTEIN CODING REGIONS AND INTRON/EXON BOUNDARIES OF THE BRCA1 AND BRCA2 GENES USING GENOMIC DNA OBTAINED FROM WHOLE BLOOD SPECIMENS COLLECTED IN EDTA. SINGLE NUCLEOTIDE VARIANTS AND SMALL INSERTIONS AND DELETIONS (INDELS) ARE IDENTIFIED BY POLYMERASE CHAIN REACTION (PCR) AND SANGER SEQUENCING. LARGE DELETIONS AND DUPLICATIONS IN BRCA1 AND BRCA2 ARE DETECTED USING MULTIPLEX PCR. RESULTS OF THE TEST ARE USED AS AN AID IN IDENTIFYING OVARIAN CANCER PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA VARIANTS ELIGIBLE FOR TREATMENT WITH LYNPARZA (OLAPARIB). THIS ASSAY IS FOR PROFESSIONAL USE ONLY AND IS TO BE PERFORMED ONLY AT MYRIAD GENETIC LABORATORIES, A SINGLE LABORATORY SITE LOCATED AT 320 WAKARA WAY, SALT LAKE CITY, UT 84108.|1|1
3|P140020|S018|BRACAnalysis CDx|cancer-related germline gene mutation detection system|2018-09-21 00:00:00|2018-12-19 00:00:00|false|true|Approval for the BRACAnalysis CDxÂ®, for gBRCA mutated ovarian cancer patients maintenance monotherapy with LynparzaÂ® (olaparib).|1|1
4|P140020|S019|BRACAnalysis CDx|cancer-related germline gene mutation detection system|2019-07-02 00:00:00|2019-12-27 00:00:00|false|true|Approval for expansion of the indications for use as a companion diagnostic for LYNPARZA (olaparib) inpancreatic cancer patients|1|1
5|P140020|S016|BRACAnalysis CDx|cancer-related germline gene mutation detection system|2018-06-29 00:00:00|2018-10-16 00:00:00|false|true|Approval for extending the label claim of the BRACAnalysis CDxÂ® to include treatment and maintenance indications for RubracaÂ® (rucaparib) in ovarian cancer patients.|1|1
6|P120022|S018|therascreen EGFR RGQ PCR Kit|somatic gene mutation detection system|2018-02-16 00:00:00|2018-09-27 00:00:00|false|true|Approval for to extend the intended use of the therascreenÂ® EGFR RGQ PCR Kit to include the selection of patients with NSCLC for whom dacomitinib is indicated.|2|1
7|P120022|null|THERASCREEN EGFR RGQ PCR KIT|somatic gene mutation detection system|2012-11-30 00:00:00|2013-07-12 00:00:00|false|true|APPROVAL FOR THE THERASCREENÂ® EGFR RGQ PCR KIT. THIS DEVICE IS INDICATED FOR: THE THERASCREENÂ® EGFR RGQ PCR KIT IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF EXON 19 DELETIONS AND EXON 21 (L858R) SUBSTITUTION MUTATIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE) NONSMALL CELL LUNG CANCER (NSCLC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED TO SELECT PATIENTS WITH NSCLC FOR WHOM GILOTRJF (AFATINIB), AN EGFR TYROSINE KINASE INHIBITOR (TKI), IS INDICATED. SAFETY AND EFFICACY OF GILOTRIF (AFATINIB) HAVE NOT BEEN ESTABLISHED IN PATIENTS WHOSE TUMORS HAVE L861Q, G719X, 87681, EXON 20 INSERTIONS, AND T790M MUTATIONS, WHICH ARE ALSO DETECTED BY THE THERASCREENÂ® EGFR RGQ PCR KIT. SPECIMENS ARE PROCESSED USING THE QIAAMPÂ® DSP DNA FFPE TISSUE KIT FOR MANUAL SAMPLE PREPARATION AND THE ROTOR-GENEÂ® Q MDX INSTRUMENT FOR AUTOMATED AMPLIFICATION ANDDETECTION.|2|1
8|P120019|S019|Cobas EGFR Mutation Test v2, Cobas DNA and cfDNA Sample Preparation Kit|somatic gene mutation detection system|2018-02-23 00:00:00|2018-08-22 00:00:00|false|true|Approval for the cobasÂ® EGFR Mutation Test v2. The device is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood.The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling:Table 1Drug FFPET PlasmaTARCEVAÂ® (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858RTAGRISSOÂ® (osimertinib) Exon 19 deletions, L858R and T790M Exon 19 deletions, L858R and T790M* IRESSAÂ® (gefitinib) Exon 19 deletions and L858R Exon 19 deletions and L858RPatients with positive cobasÂ® EGFR Mutation Test v2 test results using plasma specimens for the presence of the EGFR mutations listed above are eligible for treatment with the corresponding drug as indicated in Table 1 (see Note* for T790M). Patients who are negative for these mutations by this test using plasma specimens should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.Note: *The efficacy of TAGRISSOÂ® (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Drug safety and efficacy have not been established for the following EGFR mutations also detected by the cobasÂ® EGFR Mutation Test v2:Table 2Drug FFPET PlasmaTARCEVAÂ® (erlotinib) G719X, Exon 20 insertions, T790M, S768I and L861Q G719X, Exon 20 insertions, T790M, S768I and L861QTAGRISSOÂ® (osimertinib) G719X, Exon 20 insertions, S768I, and L861Q G719X, Exon 20 insertions, S768I, and L861QIRESSAÂ® (gefitinib) G719X, Exon 20 insertions, T790M, S768I and L861Q G719X, Exon 20 insertions, T790M, S768I and L861QFor manual sample preparation, FFPET specimens are processed using the cobasÂ® DNA Sample Preparation Kit and plasma specimens are processed using the cobasÂ® cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection.|3|1
9|P120019|S007|COBAS EGFR MUTATION TEST V2|somatic gene mutation detection system|2015-05-28 00:00:00|2015-11-13 00:00:00|false|true|APPROVAL FOR THE COBASÂ® EGFR MUTATION TEST V2. THIS DEVICE IS INDICATED FOR:THE COBASÂ® EGFR MUTATION TEST V2 IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF DEFINED MUTATIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED TUMOR TISSUE (FFPET) FROM NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS. THE TEST IS INTENDED TO AID IN IDENTIFYING PATIENTS WITH NSCLC WHOSE TUMORS HAVE DEFINED EGFR MUTATIONS AND FOR WHOM SAFETY AND EFFICACY OF A DRUG HAVE BEEN ESTABLISHED AS FOLLOWS: TARCEVAÂ® (ERLOTINIB)/EXON 19 DELETIONS AND L858R AND TAGRISSOÂ® (OSIMERTINIB) T790M. DRUG SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED FOR THE FOLLOWING EGFR MUTATIONS ALSO DETECTED BY THE COBASÂ® EGFR MUTATION TEST V2: TARCEVAÂ® (ERLOTINIB)/G719X, EXON 20 INSERTIONS, T790M, S768I AND L861Q/TAGRISSOÂ® (OSIMERTINIB)/G719X, EXON 19 DELETIONS, L858R, EXON 20 INSERTIONS, S768I, AND L861Q. FOR MANUAL SAMPLE PREPARATION, FFPET SPECIMENS ARE PROCESSED USING THE COBASÂ® DNA SAMPLE PREPARATION KIT AND THE COBAS Z 480 ANALYZER IS USED FOR AUTOMATED AMPLIFICATION AND DETECTION. |3|1
10|P120019|S018|cobas EGFR Mutation Test v2|somatic gene mutation detection system|2017-11-30 00:00:00|2018-04-18 00:00:00|false|true|The cobasÂ® EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood.The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling:Table 1 Drug FFPET PlasmaTARCEVAÂ® (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858RTAGRISSOÂ® (osimertinib) Exon 19 deletions, L858R and T790M Exon 19 deletions, L858R and T790M*Patients with positive cobasÂ® EGFR Mutation Test v2 test results using plasma specimens for the presence of the EGFR mutations listed above are eligible for treatment with the corresponding drug as indicated in Table 1 (see Note* for T790M). Patients who are negative for these mutations by this test using plasma specimens should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.*The efficacy of TAGRISSOÂ® (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained. Drug safety and efficacy have not been established for the following EGFR mutations also detected by the cobasÂ® EGFR Mutation Test v2: Table 2 Drug FFPET Plasma TARCEVAÂ® (erlotinib) G719X, Exon 20 insertions, T790M, S768I and L861Q G719X, Exon 20 insertions, T790M, S768I and L861Q TAGRISSOÂ® (osimertinib) G719X, Exon 20 insertions, S768I, and L861Q G719X, Exon 20 insertions, S768I, and L861QFor manual sample preparation, FFPET specimens are processed using the cobasÂ® DNA Sample Preparation Kit and plasma specimens are processed using the cobasÂ® cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection.|3|1
11|P120019|S016|cobas EGFR Mutation Test v2|somatic gene mutation detection system|2017-10-27 00:00:00|2018-04-18 00:00:00|false|true|Approval of the cobasÂ® EGFR Mutation Test v2. The device is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood. The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling:Table 1Drug FFPET PlasmaTARCEVAÂ® (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858RTAGRISSOÂ® (osimertinib) Exon 19 deletions, L858R, and T790M T790M*Patients with positive cobasÂ® EGFR Mutation Test v2 test results using plasma specimens for the presence of the EGFR mutations listed above are eligible for treatment with the corresponding drug as indicated in Table 1 (see Note* for T790M). Patients who are negative for these mutations by this test using plasma specimens should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.*The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Drug safety and efficacy have not been established for the following EGFR mutations also detected by the cobasÂ® EGFR Mutation Test v2. Table 2Drug FFPET PlasmaTARCEVAÂ® (erlotinib) G719X, Exon 20 insertions, T790M, S768I, and L861Q G719X, Exon 20 insertions, T790M, S768I, and L861QTAGRISSOÂ® (osimertinib) G719X, Exon 20 insertions, S768I, and L861Q G719X, Exon 19 deletions, L858R, Exon 20 insertions, S768I, and L861QFor manual sample preparation, FFPET specimens are processed using the cobasÂ® DNA Sample Preparation Kit and plasma specimens are processed using the cobasÂ® cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection.|3|1
12|P120019|S031|cobas EGFR Mutation Test v2|somatic gene mutation detection system|2020-04-30 00:00:00|2020-10-27 00:00:00|false|true|Approval for cobasÂ® EGFR Mutation Test v2 label expansion to obtain companion diagnostic group labeling claim for EGFR Tyrosine Kinase Inhibitors (TKI) for specific EGFR mutations detected by the test.|3|1
13|P120019|null|COBAS EGFR MUTATION TEST|somatic gene mutation detection system|2012-11-08 00:00:00|2013-05-14 00:00:00|false|true|APPROVAL FOR THE COBASÂ® EGFR MUTATION TEST. THE COBASÂ® EGFR MUTATION TEST IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF EXON 19 DELETIONS AND EXON 21 (L858R) SUBSTITUTION MUTATIONS OFTHE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPET) HUMAN NON-SMALL CELL LUNG CANCER (NSCLC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED AS AN AID IN SELECTING PATIENTS WITH METASTATIC NSCLC FOR WHOM TARCEVAÂ® (ERLOTINIB), AN EGFR TYROSINE KINASE INHIBITOR (TK1), IS INDICATED. SPECIMENS ARE PROCESSED USING THE COBASÂ® DNA SAMPLE PREPARATION KIT FOR MANUAL SAMPLE PREPARATION AND THE COBAS Z 480 ANALYZER FOR AUTOMATED AMPLIFICATION AND DETECTION.|3|1
14|P150013|S011|PD-L1 IHC 22C3 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2018-06-25 00:00:00|2018-08-16 00:00:00|false|true|Approval for the PD-L1 IHC 22C3 pharmDx. The device is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, cervical cancer and urothelial carcinoma tissues using EnVision FLEX visualization system on Autostainer Link 48. Non-Small Cell Lung Cancer (NSCLC)PD-L1 protein expression in NSCLC is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS >= 1% and high PD-L1 expression if TPS >= 50%. PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDAÂ® (pembrolizumab). See the KEYTRUDAÂ® product label for expression cutoff values guiding therapy in specific clinical circumstances. Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma PD-L1 protein expression in gastric or GEJ adenocarcinoma is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. The specimen should be considered to have PD-L1 expression if CPS >= 1. PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab). Cervical Cancer PD-L1 protein expression in cervical cancer is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. The specimen should be considered to have PD-L1 expression if CPS >= 1. PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying cervical cancer patients for treatment with KEYTRUDAÂ® (pembrolizumab). Urothelial CarcinomaPD-L1 protein expression in urothelial carcinoma is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. The specimen should be considered to have PD-L1 expression if CPS >= 10. PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying urothelial carcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab). See the KEYTRUDAÂ® product label for specific clinical circumstances guiding PD-L1 testing.|4|1
15|P150013|S014|PD-L1 IHC 22C3 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2019-01-18 00:00:00|2019-06-10 00:00:00|false|true|Approval for the PD-L1 IHC 22C3 pharmDx. This is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and gastric or gastroesophageal junction (GEJ) adenocarcinoma, cervical cancer, urothelial carcinoma and head and neck squamous cell carcinoma (HNSCC) tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression in NSCLC is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity.PD-L1 protein expression in gastric or GEJ adenocarcinoma, cervical cancer, urothelial carcinoma and HNSCC is determined by using Combined Positive Score (CPS), which is the number of PDL1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.Companion Diagnostic Indications Tumor Indication* PD-L1 Expression Level Intended UseNSCLC TPS >= 1%, PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDAÂ® (pembrolizumab). *Gastric or GEJ adenocarcinoma CPS >= 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab).Cervical Cancer CPS >= 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying cervical cancer patients for treatment with KEYTRUDAÂ® (pembrolizumab).Urothelial Carcinoma CPS >= 10 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying urothelial carcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab). *HNSCC CPS >= 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying head and neck squamous cell carcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab). * **See the KEYTRUDAÂ® product label for specific clinical circumstances guiding PD-L1 testing.|4|1
16|P150013|S024|PD-L1 IHC 22C3 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2022-01-31 00:00:00|2022-02-08 00:00:00|false|true|Approval for the removal of the gastric or gastroesophageal junction (GEJ) adenocarcinoma indication from the device labeling. |4|1
17|P150013|S001|PD-L1 IHC 22C3 PHARMDX|immunohistochemistry assay, antibody, programmed death-ligand 1|2015-12-31 00:00:00|2016-10-24 00:00:00|false|true|Approval for PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS greater than or equal to 1% and high PD-L1 expression if TPS is greater than or equal to 50%. PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDAÂ® (pembrolizumab). See the KEYTRUDAÂ® product label for expression cutoff values guiding therapy in specific clinical circumstances. This device is for in vitro diagnostic use. |4|1
18|P150013|S023|PD-L1 IHC 22C3 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2021-11-17 00:00:00|2021-11-23 00:00:00|false|true|Approved the removal of the urothelial carcinoma (UC) indication from the device intended use statement and labeling. |4|1
19|P150013|S021|PD-L1 IHC 22C3 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2020-08-31 00:00:00|2021-02-22 00:00:00|false|true|Approval for the PD-L1 IHC 22C3 pharmDX as a companion diagnostic device to detect PD-L1 protein (Tumor Proportion Score ?50%) in patients with non-small cell lung cancer (NSCLC) for treatment with LIBTAYO. |4|1
20|P150013|S020|PD-L1 IHC 22C3 pharmDX|immunohistochemistry assay, antibody, programmed death-ligand 1|2020-06-29 00:00:00|2020-11-13 00:00:00|false|true|Approval for the PD-L1 IHC 22C3 pharmDX for expanding the indications to include detection of PD-L1 protein in patients with triple-negative breast cancer (TNBC) for treatment with KEYTRUDA. |4|1
21|P150013|null|PD-L1 IHC 22C3 PHARMDX|immunohistochemistry assay, antibody, programmed death-ligand 1|2015-04-06 00:00:00|2015-10-02 00:00:00|false|true|APPROVAL FOR THE PD-L1 IHC 22C3 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING: PD-L1 IHC 22C3 PHARMDX IS A QUALITATIVE IMMUNOHISTOCHEMICAL ASSAY USING MONOCLONAL MOUSE ANTI-PD-L1, CLONE 22C3 ANTIBODY INTENDED FOR USE IN THE DETECTION OF PD-L1PROTEIN IN FORMALIN FIXED, PARAFFIN EMBEDDED (FFPE) NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48. PD-L1 PROTEIN EXPRESSION IS DETERMINED BY USING TUMOR PROPORTION SCORE (TPS), WHICH IS THE PERCENTAGE OF VIABLE TUMOR CELLS SHOWING PARTIAL OR COMPLETE MEMBRANE STAINING. THE SPECIMEN SHOULD BE CONSIDERED PD-L1 POSITIVE IF TPS >= 50% OF THE VIABLE TUMOR CELLS EXHIBIT MEMBRANE STAINING AT ANY INTENSITY. PD-L1 IHC 22C3 PHARMDX IS INDICATED AS AN AID IN IDENTIFYING NSCLC PATIENTS FOR TREATMENT WITH KEYTRUDA (PEMBROLIZUMAB).|4|1
22|P150013|S009|PD-L1 IHC 22C3 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2018-01-29 00:00:00|2018-06-12 00:00:00|false|true|Approval for the PD-L1 IHC 22C3 pharmDx. PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma and cervical cancer tissues using EnVision FLEX visualization system on Autostainer Link 48.Non-Small Cell Lung Cancer (NSCLC)PD-L1 protein expression in NSCLC is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS >= 1% and high PD-L1 expression if TPS >= 50%.PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDAÂ® (pembrolizumab). See the KEYTRUDAÂ® product label for expression cutoff values guiding therapy in specific clinical circumstances.Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaPD-L1 protein expression in gastric or GEJ adenocarcinoma is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. The specimen should be considered to have PD-L1 expression if CPS >=1.PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab).Cervical CancerPD-L1 protein expression in cervical cancer is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. The specimen should be considered to have PD-L1 expression if CPS >= 1.PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying cervical cancer patients for treatment with KEYTRUDAÂ® (pembrolizumab).|4|1
23|P150013|S006|PD-L1 IHC 22C3 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2017-04-19 00:00:00|2017-09-22 00:00:00|false|true|Approval for the PD-L1 IHC 22C3 pharmDx for expanding the indications to include gastric cancer patients. This device is indicated for the followingPD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and gastric or gastroesophageal junction (GEJ) adenocarcinoma tissues using EnVision FLEX visualization system on Autostainer Link 48. Non-Small Cell Lung Cancer (NSCLC)PD-L1 protein expression in NSCLC is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS ?1% and high PD-L1 expression if TPS ?50%. PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDAÂ® (pembrolizumab). See the KEYTRUDAÂ® product label for expression cutoff values guiding therapy in specific clinical circumstances.Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma PD-L1 protein expression in gastric or GEJ adenocarcinoma is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100 . The specimen should be considered to have PD-L1 expression if CPS ? 1.PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab). |4|1
24|P150013|S016|PD-L1 IHC 22C3 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2019-02-25 00:00:00|2019-07-30 00:00:00|false|true|Approval for the PD-L1 IHC 22C3 pharmDx. PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using monoclonal mouse anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC), cervical cancer, urothelial carcinoma and head and neck squamous cell carcinoma (HNSCC) tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression in NSCLC is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. PD-L1 protein expression in gastric or GEJ adenocarcinoma, ESCC, cervical cancer, urothelial carcinoma and HNSCC is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100.Companion Diagnostic IndicationsTumor Indication PD-L1 Expression Level Intended UseNSCLC TPS greater than or equal to 1% PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDAÂ® (pembrolizumab). **Gastric or GEJ Adenocarcinoma CPS greater than or equal to 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab).ESCC CPS greater than or equal to 10 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying esophageal squamous cell cancer patients for treatment with KEYTRUDAÂ® (pembrolizumab). Cervical Cancer CPS greater than or equal to 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying cervical cancer patients for treatment with KEYTRUDAÂ® (pembrolizumab).Urothelial Carcinoma CPS greater than or equal to 10 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying urothelial carcinoma patients for treatment with KEYTRUDAÂ® (pembrolizumab). **HNSCC CPS 1 PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying HNSCC patients for treatment with KEYTRUDAÂ® (pembrolizumab). ****See the KEYTRUDAÂ® product label for specific clinical circumstances guiding PD-L1 testing.For in vitro diagnostic use.|4|1
25|P170041|null|Abbott RealTime IDH1|somatic gene mutation detection system|2017-12-05 00:00:00|2018-07-20 00:00:00|false|true|Approval for the Abbott RealTime IDH1. Abbott RealTime IDH1 is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs) coding five IDH1 R132 mutations (R132C, R132H, R132G, R132S, and R132L) in DNA extracted from human blood (EDTA) or bone marrow (EDTA). Abbott RealTime IDH1 is for use with the Abbott m2000rt System.Abbott RealTime IDH1 is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVOÂ® (ivosidenib). This test is for prescription use only.|5|1
26|K173492|null|MRDx BCR-ABL Test, MRDx BCR-ABL Test Software|null|2017-11-13 00:00:00|2017-12-22 00:00:00|false|true|null|6|4
27|P170019|S017|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2020-01-31 00:00:00|2020-10-23 00:00:00|false|true|Approval order to expand the intended use of FoundationOneÂ®CDx (F1CDx) to include NTRK1/2/3 fusions in patients with solid tumors who may benefit from treatment with VITRAKVIÂ® (larotrectinib).|7|1
28|P170019|S006|FoundationOne CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2018-12-26 00:00:00|2019-12-03 00:00:00|false|true|Approval order for extending the label claim to include an indication for PIQRAY (alpelisib) in breast cancer patients with PIK3CA C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y alterations. |7|1
29|P170019|S011|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2019-10-17 00:00:00|2020-05-06 00:00:00|false|true|Approval to include a companion diagnostic indication for detection of MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping in non-small cell lung cancer patients who may benefit from treatment with TABRECTA (capmatinib).|7|1
30|P170019|S016|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2020-01-21 00:00:00|2020-06-16 00:00:00|false|true|Approval order to expand the intended use of FoundationOneÂ®CDx (F1CDx) to include high tumor mutational burden (TMB) at the cut-off of greater than or equal to 10 mutations per megabase (mut/Mb) in patients with solid tumors who may benefit from treatment with KEYTRUDAÂ® (pembrolizumab).|7|1
31|P170019|S033|FoundationOne CDx (FICDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2021-12-23 00:00:00|2022-03-16 00:00:00|false|true|for FoundationOne CDx (FICDx) label expansion to obtain companion diagnostic group labeling claim for non-small cell lung cancer patients harboring EGFR exon 19 deletions or EGFR exon 21 L858R mutations for treatment with any one of the FDA-approved EGFR Tyrosine Kinase Inhibitors (TKI) .|7|1
32|P170019|S008|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2019-04-09 00:00:00|2019-07-01 00:00:00|false|true|Approval order for extending the label claim to include an indication for TAGRISSO (osimertinib) in non-small cell lung cancer patients with EGFR exon 19 deletions and EGFR exon 21 L858R alterations. |7|1
33|P170019|S029|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2021-04-19 00:00:00|2022-02-18 00:00:00|false|true|Approval order to expand the intended use of FoundationOneÂ®CDx (F1CDx) to include a companion diagnostic (CDx) indication for the detection of microsatellite instability High (MSI-H) status in patients with solid tumors who may benefit from treatment with KEYTRUDAÂ® (pembrolizumab).|7|1
34|P170019|null|FoundationOne CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2017-06-02 00:00:00|2017-11-30 00:00:00|false|true|Approval for the FoundationOne CDx (F1CDx). This device is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. The F1CDx assay is a single-site assay performed at Foundation Medicine, Inc.Table 1: Companion diagnostic indicationsIndication: Non-small cell lung cancer (NSCLC). - Biomarker: EGFR exon 19 deletions and EGFR exon 21 L858R alterations. Therapy: GilotrifÂ® (afatinib), IressaÂ® (gefitinib), or TarcevaÂ® (erlotinib). - Biomarker: EGFR exon 20 T790M alterations. Therapy: TagrissoÂ® (osimertinib). - Biomarker: ALK rearrangements. Therapy: AlecensaÂ® (alectinib), XalkoriÂ® (crizotinib), or ZykadiaÂ® (ceritinib). - Biomarker: BRAF V600E. Therapy: TafinlarÂ® (dabrafenib) in combination with MekinistÂ® (trametinib).Indication: Melanoma. - Biomarker: BRAF V600E. Therapy: TafinlarÂ® (dabrafenib) or ZelborafÂ® (vemurafenib) - Biomarker: BRAF V600E and V600K. Therapy: MekinistÂ® (trametinib) or CotellicÂ® (cobimetinib) in combination with ZelborafÂ® (vemurafenib).Indication: Breast cancer. Biomarker: ERBB2 (HER2) amplification. Therapy: HerceptinÂ® (trastuzumab), KadcylaÂ® (ado-trastuzumab-emtansine), orPerjetaÂ® (pertuzumab).Indication: Colorectal cancer. - Biomarker: KRAS wild-type (absence of mutations in codons 12 and 13). Therapy: ErbituxÂ® (cetuximab) - Biomarker: KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4). Therapy: VectibixÂ® (panitumumab)Indication: Ovarian cancer. Biomarker: BRCA1/2 alterations. Therapy: RubracaÂ® (rucaparib)|7|1
35|P170019|S021|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2020-10-29 00:00:00|2021-05-28 00:00:00|false|true|Approval to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic indication for FGFR2 fusion/rearrangements in patients with Cholangiocarcinoma who may benefit from treatment with Truseltiq (infigratinib).|7|1
36|P170019|S013|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2019-10-31 00:00:00|2020-04-17 00:00:00|false|true|Approval order for extending the label claim to include an indication for PEMAZYRE(pemigatinib)in cholangiocarcinoma patients with FGFR2 fusions and select rearrangements. |7|1
37|P170019|S030|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2021-07-01 00:00:00|2022-01-19 00:00:00|false|true|Approval to expand the intended use of FoundationOne CDx (F1CDx) to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic indication for identifying patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, who may benefit from treatment with atezolizumab (Tecentriq) in combination with cobimetinib and vemurafenib.|7|1
38|P170019|S023|FoundationOne CDx (F1CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2020-12-01 00:00:00|2021-06-30 00:00:00|false|true|Approval for Expanding the indications for use to include a CDx indication for detecting ALK rearrangements in non-small cell lung cancer patients who may be candidates for brigatinib treatment.|7|1
39|P170019|S004|FoundationOne CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2018-09-24 00:00:00|2019-07-01 00:00:00|false|true|Approval order for extending the label claim to include an indication for LYNPARZA (olaparib) in ovarian cancer patients with BRCA1/2 alterations.|7|1
40|P170019|S015|FoundationOne CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2019-12-16 00:00:00|2020-05-19 00:00:00|false|true|Approval to expand the intended use of FoundationOneÂ®CDx to include a companion diagnostic indication for homologous recombination repair (HHR) gene alterations in patients with metastatic castration resistant prostate cancer who may benefit from treatment with LynparzaÂ®(olaparib).|7|1
41|P170019|S025|FoundationOne CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2020-12-28 00:00:00|2021-11-10 00:00:00|false|true|Approval for the FoundationOne CDx. The device is intended use is expanded to grant companion diagnostic group labeling claims for melanoma patients harboring BRAF V600E alterations for BRAF inhibitor monotherapy group claim and for BRAF V600E or V600K alterations for BRAF/MEK inhibitor combination group claim. |7|1
42|P140025|S014|VENTANA ALK (D5F3) CDx Assay|immunohistochemistry assay, antibody, anaplastic lymphoma kinase|2020-11-16 00:00:00|2021-03-03 00:00:00|false|true|Approval for inclusion of an indication for LORBRENA ((lorlatinib). The device will be marketed under the trade name VENTANA ALK (D5F3) CDx Assay and is indicated for:VENTANA ALK (D5F3) CDx Assay is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT or BenchMark ULTRA automated staining instrument. It is indicated as an aid in identifying patients eligible for treatment with XALKORIÂ® (crizotinib), ZYKADIAÂ® (ceritinib), or ALECENSAÂ® (alectinib) or LORBRENAÂ® (lorlatinib).This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.This product is intended for in vitro diagnostic (IVD) use.|8|1
43|P140025|null|VENTANA ALK (D5F3) CDX ASSAY|immunohistochemistry assay, antibody, anaplastic lymphoma kinase|2014-11-14 00:00:00|2015-06-12 00:00:00|false|true| APPROVAL FOR THE VENTANA ALK (D5F3) CDX ASSAY. THIS DEVICE IS INDICATED FOR THE FOLLOWING:VENTANA ALK (D5F3) CDX ASSAY IS INTENDED FOR THE QUALITATIVE DETECTION OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SMALL CELL LUNG CARCINOMA (NSCLC) TISSUE STAINED WITH A BENCHMARK XT AUTOMATED STAINING INSTRUMENT. IT IS INDICATED AS AN AID IN IDENTIFYING PATIENTS ELIGIBLE FOR TREATMENT WITH XALKORIÂ® (CRIZOTINIB).|8|1
44|P140025|S006|VENTANA ALK (D5F3) CDx Assay|immunohistochemistry assay, antibody, anaplastic lymphoma kinase|2017-06-07 00:00:00|2017-11-06 00:00:00|false|true|Approval for the VENTANA ALK (D5F3) CDx Assay. The device is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT or BenchMark ULTRA automated staining instrument. It is indicated as an aid in identifying patients eligible for treatment with XALKORIÂ® (crizotinib) or ZYKADIAÂ® (ceritinib) or ALECENSAÂ® (alectinib).|8|1
45|P170005|null|Abbott RealTime IDH2|somatic gene mutation detection system|2017-02-02 00:00:00|2017-08-01 00:00:00|false|true|Approval for the Abbott RealTime IDH2. The device is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs) coding nine IDH2 mutations (R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W) in DNA extracted from blood (EDTA) or human bone marrow (EDTA). Abbott RealTime IDH2 is for use with the Abbott m2000rt System.Abbott RealTime IDH2 is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 (IDH2) mutation for treatment with IDHIFAÂ® (enasidenib).|9|1
46|P160038|null|Praxis Extended RAS Panel|next generation sequencing oncology panel, somatic or germline variant detection system|2016-09-02 00:00:00|2017-06-29 00:00:00|false|true|Approval for the Praxis Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue samples. The Praxisâ„¢ Extended RAS Panel is indicated to aid in the identification of patients with colorectal cancer for treatment with VectibixÂ® (panitumumab) based on a no mutation detected test result. The test is intended to be used on the Illumina MiSeqDxÂ® instrument.|10|1
47|P160045|null|Oncomine Dx Target Test|next generation sequencing oncology panel, somatic or germline variant detection system|2016-10-17 00:00:00|2017-06-22 00:00:00|false|true|Approval for the The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high throughput, parallel-sequencing technology to detect single nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC) using the Ion PGM Dx System. The test is indicated to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling.Table 1. List of variants for therapeutic useGene Variant Targeted therapyBRAF BRAF V600E TAFINLARÂ® (dabrafenib) in combination with MEKINISTÂ® (trametinib)ROS1 ROS1 fusions XALKORIÂ® (crizotinib)EGFR L858R, Exon 19 deletions IRESSAÂ® (gefitinib)Safe and effective use has not been established for selecting therapies using this device for the variants in Table 1 in tissue types other than NSCLC.Results other than those listed in Table 1 are indicated for use only in patients who have already been considered for all appropriate therapies (including those listed in Table 1). Analytical performance using NSCLC specimens has been established for the variants listed in Table 2.Table 2. List of variants with established analytical performance onlyGene Variant ID Nucleotide changeKRAS COSM512 c.34_35delGGinsTTKRAS COSM516 c.34G>TMET COSM707 c.3029C>TPIK3CA COSM754 c.1035T>AThe test is not indicated to be used for standalone diagnostic purposes, screening, monitoring, risk assessment, or prognosis.|11|1
48|P160045|S029|Oncomine Dx Target Test (ODxT Test)|next generation sequencing oncology panel, somatic or germline variant detection system|2021-05-03 00:00:00|2021-09-15 00:00:00|false|true|Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of EGFR exon 20 insertion mutations in non-small cell lung cancer patients who may benefit from the treatment with EXKIVITY (mobocertinib).|11|1
49|P160045|S019|Oncomine Dx Target Test|next generation sequencing oncology panel, somatic or germline variant detection system|2020-04-01 00:00:00|2020-09-04 00:00:00|false|true|Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of RET fusions in non-small cell lung cancer patients who may benefit from treatment with GAVRETO (pralsetinib).|11|1
50|P160045|S027|Oncomine™ Dx Target Test|next generation sequencing oncology panel, somatic or germline variant detection system|2021-02-22 00:00:00|2021-12-01 00:00:00|false|true|Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of EGFR exon 20 insertion mutations in non-small cell lung cancer patients who may benefit from treatment with RYBREVANT (amivantamab-vmjw).|11|1
51|P160045|S028|Oncomine™ Dx Target Test|next generation sequencing oncology panel, somatic or germline variant detection system|2021-03-02 00:00:00|2021-08-25 00:00:00|false|true|Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of single nucleotide variants in IDH1 in cholangiocarcinoma patients who may benefit from treatment with TIBSOVO (ivosidenib).|11|1
52|P160040|null|LeukoStrat CDx FLT3 Mutation Assay|somatic gene mutation detection system|2016-09-02 00:00:00|2017-04-28 00:00:00|false|true|Approval for the LeukoStratÂ® CDx FLT3 Mutation Assay is a PCR-based, in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and the tyrosine kinase domain mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML). The LeukoStratÂ® CDx FLT3 Mutation Assay is used as an aid in the selection of patients with AML for whom RYDAPT (midostaurin) treatment is being considered. The LeukostratÂ® CDx FLT3 Mutation Assay is to be performed only at Laboratory for Personalized Molecular Medicine (LabPMM) LLC, a single site laboratory located at 6330 Nancy Ridge Dr., San Diego, CA 92121.|12|1
53|P160018|null|FoundationFocus CDxBRCA|next generation sequencing oncology panel, somatic or germline variant detection system|2016-06-30 00:00:00|2016-12-19 00:00:00|false|true|Approval for The FoundationFocus CDxBRCA is a next generation sequencing based in vitro diagnostic device for qualitative detection of BRCA1 and BRCA2 alterations in formalin-fixed paraffin-embedded (FFPE) ovarian tumor tissue. The FoundationFocus CDxBRCA assay detects sequence alterations in BRCA1 and BRCA2 (BRCA1/2) genes. Results of the assay are used as an aid in identifying ovarian cancer patients for whom treatment with Rubraca (rucaparib) is being considered. If a patient is positive for any of the deleterious alterations specified in the BRCA1/2 classification, the patient may be eligible for treatment with Rubraca. This assay is to be performed at Foundation Medicine, Inc., a single laboratory site located at 150 Second Street, Cambridge, Massachusetts.|13|1
54|P150041|null|VYSIS CLL FISH PROBE KIT|fluorescence in situ hybridization, chromosome 17p deletion (tp53)|2015-10-30 00:00:00|2016-04-11 00:00:00|false|true|The Vysis CLL FISH Probe Kit is a test to detect deletion of the LSI TP53 probe target via fluorescence in situ hybridization (FISH) in peripheral blood specimens from patients with B-cell chronic lymphocytic leukemia (CLL).The test is indicated for detecting deletion of the LSI TP53 probe target (17p-) as an aid in identifying those patients with CLL for whom treatment with VENCLEXTAÂ® (venetoclax) is indicated. Vysis CLL FISH Probe Kit is not intended for monitoring of residual disease.|14|1
55|H140006|null|KIT D816V ASSAY|somatic gene mutation detection system|2014-11-26 00:00:00|2015-12-18 00:00:00|false|true|Approval for the kit d816v mutation detection by pcr for gleevec eligibility in aggressive systemic mastocytosis (asm). Kit d816v mutation detection by pcr for gleevec eligibility in aggressive systemic mastocytosis (asm) (referred to as the Â¿kit d816v assayÂ¿) is an in vitro diagnostic test intended for qualitative polymerase chain reaction (pcr) detection of kit d816v mutational status from fresh bone marrow samples of patients with aggressive systemic mastocytosis. The kit d816v mutational assay is indicated as an aid in the selection of asm patients for whom gleevecÂ® (imatinib mesylate) treatment is being considered. This assay is for professional use only and is to be performed at a single laboratory site. |15|3
56|H140005|null|PDGFRB FISH ASSAY|fluorescence in situ hybridization, platelet-derived growth factor receptor, beta polypeptide (pdgfrb), rearrangement|2014-11-26 00:00:00|2015-12-18 00:00:00|false|true|Approval for the pdgfrb fish for gleevec eligibility in myelodysplastic syndrome/myeloproliferative disease (mds/mpd). This device is indicated for the qualitative detection of pdgfrb gene rearrangement from fresh bone marrow samples of patients with mds/mpd with a high index of suspicion based on karyotyping showing a 5q31~33 anomaly. The pdgfrb fish assay is indicated as an aid in the selection of mds/mpd patients for whom gleevec (imatinib mesylate) treatment is being considered. This assay is for professional use only and is to be performed at a single laboratory site. |16|3
57|P140023|null|COBAS KRAS MUTATION TEST|somatic gene mutation detection system|2014-10-23 00:00:00|2015-05-07 00:00:00|false|true|APPROVAL FOR THE COBAS KRAS MUTATION TEST. THIS DEVICE IS INDICATED FOR THE FOLLOWING:THE COBAS KRAS MUTATION TEST, FOR USE WITH THE COBAS 4800 SYSTEM, IS A REAL-TIME PCR TEST FOR THE DETECTION OF SEVEN SOMATIC MUTATIONS IN CODONS 12 AND 13 OF THE KRAS GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED HUMAN COLORECTAL CANCER (CRC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED AS AN AID IN THE IDENTIFICATION OF CRC PATIENTS FOR WHOM TREATMENT WITH ERBITUX (CETUXIMAB) OR WITH VECTIBIX (PANITUMUMAB) MAY BE INDICATED BASED ON A NO MUTATION DETECTED RESULT.SPECIMENS ARE PROCESSED USING THE COBAS DNA SAMPLE PREPARATION KIT FOR MANUAL SAMPLE PREPARATION AND THE COBAS Z 480 ANALYZER FOR AUTOMATED AMPLIFICATION AND DETECTION.|17|1
58|P140023|S004|COBAS KRAS MUTATION TEST|somatic gene mutation detection system|2016-02-29 00:00:00|2016-09-24 00:00:00|false|true|The cobasÂ® KRAS Mutation Test, for use with the cobasÂ® 4800 System, is a real-time PCR test for the detection of mutations in codons 12, 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC) tumor tissue. The test is intended to be used as an aid in the identification of CRC patients who should not be treated with ErbituxÂ® (cetuximab) or with VectibixÂ® (panitumumab) when KRAS Codon 12 or 13 mutation is detected. Safety and efficacy of ErbituxÂ® (cetuximab) or VectibixÂ® (panitumumab) have not been established in patients whose tumors have Codon 61 mutation. Specimens are processed using the cobasÂ® DNA Sample Preparation Kit for manual sample preparation and the cobas z 480 analyzer for automated amplification and detection.|17|1
59|P110027|S012|therascreen KRAS RGQ PCR KIT|somatic gene mutation detection system|2021-02-10 00:00:00|2021-05-28 00:00:00|false|true|Approval for expanding the indication to aid in the identification of non-small cell lung cancer patients whose tumors harbor KRAS G12C mutations and may benefit from treatment with LUMAKRA (sotorasib). |18|1
60|P110030|null|THERASCREEN KRAS RGQ PCR KIT|somatic gene mutation detection system|2011-07-28 00:00:00|2012-07-06 00:00:00|false|true|APPROVAL FOR THE THERASCREEN KRAS RGQ PCR KIT. THIS DEVICE IS INDICATED FOR: THE THERASCREEN KRAS RGQ PCR KIT IS A REAL-TIME QUALITATIVE PCR ASSAY USED ON THE ROTORGENE Q MDX INSTRUMENT FOR THE DETECTION OF SEVEN SOMATIC MUTATIONS IN THE HUMAN KRAS ONCOGENE, USING DNA EXTRACTED FROM FORMALIN FIXED PARAFFIN-EMBEDDED (FFPE), COLORECTAL CANCER (CRC) TISSUE. THE THERASCREEN KRAS RGQ PCR KIT IS INTENDED TO AID IN THE IDENTIFICATION OF CRC PATIENTS FOR TREATMENT WITH ERBITUX (CETUXIMAB) BASED ON A KRAS NO MUTATION DETECTED TEST RESULT.|18|1
61|P110027|null|THERASCREEN KRAS RGQ PCR KIT|somatic gene mutation detection system|2011-07-25 00:00:00|2014-05-23 00:00:00|false|true|APPROVAL FOR THE THERASCREEN KRAS RGQ PCR KIT, WHICH IS TO BE USED AS A COMPANION DIAGNOSTIC FOR THE DRUG VECTIBIX (PANITUMUMAB). THIS DEVICE IS INDICATED FOR:THE THERASCREEN KRAS RGQ PCR KIT IS A REAL-TIME QUALITATIVE PCR ASSAY USED ON THE ROTOR-GENE Q MDX INSTRUMENT FOR THE DETECTION OF SEVEN SOMATIC MUTATIONS IN THE HUMAN KRAS ONCOGENE, USING DNA EXTRACTED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE), COLORECTAL CANCER (CRC) TISSUE. THE THERASCREEN KRAS RGQ PCR KIT IS INTENDED TO AID IN THE IDENTIFICATION OF CRC PATIENTS FOR TREATMENT WITH ERBITUX (CETUXIMAB) AND VECTIBIX (PANITUMUMAB) BASED ON A KRAS NO MUTATION DETECTED TEST RESULT.|18|1
62|P030044|null|DAKOCYTOMATION EGFR PHARMDX|immunohistochemistry assay, antibody, epidermal growth factor receptor|2003-09-29 00:00:00|2004-02-12 00:00:00|false|true|APPROVAL FOR THE DAKOCYTOMATION EGFR PHARMDX. THE DEVICE IS INDICATED FOR: THE EGFR PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM TO IDENTIFY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN NORMAL AND NEOPLASTIC TISSUES ROUTINELY-FIXED FOR HISTOLOGICAL EVALUATION. EGFR PHARMDX SPECIFICALLY DETECTS THE EGFR (HER1) PROTEIN IN EGFR-EXPRESSING CELLS. EGFR PHARMDX IS INDICATED AS AN AID IN IDENTIFYING COLORECTAL CANCER PATIENTS ELIGIBLE FOR TREATMENT WITH ERBITUX (CETUXIMAB).|19|1
63|P030044|S002|DAKO EGFR PHARMDX KIT|immunohistochemistry assay, antibody, epidermal growth factor receptor|2006-04-03 00:00:00|2006-09-27 00:00:00|false|true|APPROVAL FOR ADDING A NEW THERAPY VECTIBIX (PANITUMUMAB) TO INTENDED USE. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME DAKO EGFR PHARMDX KIT AND IS INDICATED FOR: THE EGFR PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM TO IDENTIFY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN NORMAL AND NEOPLATIC TISSUES ROUTINELY-FIXED FOR HISTOLOGICAL EVALUATIN. EGFR PHARMDX SPECIFICALLY DETECTS THE EGFR (HER1) PROTEIN IN EGFR-EXPRESSING CELLS. EGFR PHARMDX IS INDICATED AS AN AID IN IDENTIFYING COLORECTAL CANCER PATIENTS ELIGIBLE FOR TREATMENT WITH ERBITUX (CETUXIMAB), OR VECTIBIX (PANITUMUMAB).|19|1
64|K124065|null|FERRISCAN R2-MRI ANALYSIS SYSTEM|null|2013-01-02 00:00:00|2013-01-23 00:00:00|false|true|null|20|4
65|P040011|null|C-KIT PHARMDX|immunohistochemistry antibody assay, c-kit|2004-03-12 00:00:00|2005-06-27 00:00:00|false|true|APPROVAL FOR THE DAKOCYTOMATION C-KIT PHARMDX. DAKOCYTOMATION C-KIT PHARMDX ON THE DAKO AUTOSTAINER: THE C-KIT PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM USED ON THE DAKO AUTOSTAINER, FOR THE IDENTIFICATION OF C-KIT PROTEIN/CD117 ANTIGEN (C-KIT PROTEIN) EXPRESSION IN NORMAL AND NEOPLASTIC FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FOR HISTOLOGICAL EVALUATION. THE C-KIT PHARMDX RABBIT POLYCLONAL ANTIBODIES SPECIFICALLY DETECT THE C-KIT PROTEIN IN CD117 ANTIGEN-EXPRESSING CELLS. THE C-KIT PHARMDX IS INDICATED AS AN AID IN THE DIFFERENTIAL DIAGNOSIS OF GASTROINTESTINAL STROMAL TUMORS (GIST). AFTER DIAGNOSIS OF GIST, RESULTS FROM C-KIT PHARMDX MAY BE USED AS AN AID IN IDENTIFYING THOSE PATIENTS ELIGIBLE FOR TREATMENT WITH GLEEVEC/GLIVEC (IMATINIB MESYLATE). RESULTS FROM HEMATOXYLIN AND EOSIN (H&E) STAINS AND A PANEL OF ANTIBODIES CAN AID IN THE DIFFERENTIAL DIAGNOSIS OF GIST. INTERPRETATION MUST BE MADE BY A QUALIFIED PATHOLOGIST, WITHIN THE CONTEXT OF A PATIENT'S CLINICAL HISTORY, PROPER CONTROLS, AND OTHER DIAGNOSTIC TEST. DAKO CYTOMATION C-KIT PHARMDX FOR MANUAL USE: THE C-KIT PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM USED FOR THE IDENTIFICATION OF C-KIT PROTEIN/CD117 ANTIGEN (C-KIT PROTEIN) EXPRESSION IN NORMAL AND NEOPLASTIC FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FOR HISTOLOGICAL EVALUATION. THE C-KIT PHARMDX RABBIT POLYCLONAL. ANTIBODIES SPECIFICALLY DETECT THE C-KIT PROTEIN IN CD117 ANTIGEN-EXPRESSING CELLS. THE C-KIT PHARMDX IS INDICATED AS AN AID IN THE DIFFERENTIAL DIAGNOSIS OF GASTROINTESTINAL STROMAL TUMORS (GIST). AFTER DIAGNOSIS OF GIST, RESULTS FROM C-KIT PHARMDX MAY BE USED AS AN AID IN IDENTIFYING THOSE PATIENTS ELIGIBLE FOR TREATMENT WITH GLEEVEC/GLIVEC (IMATINIB MESYLATE). RESULTS FROM HEMATOXYLIN AND EOSIN (H&E) STAINS AND A PANEL OF ANTIBODIES CAN AID IN THE DIFFERENTIAL DIAGNOSIS OF GIST. INTERPRETATION MUST BE MADE BY A QUALIFIED PATHOLOGIST, WITHIN THE CONTEXT OF A PATIENT'S...|21|1
66|P940004|null|ONCOR(R) AMPLITECT(TM) HER/NEU(ERBB2)GENE AMPLIFI|system, test, her-2/neu, nucleic acid or serum|1994-02-14 00:00:00|1997-12-30 00:00:00|false|true|Approval for the Oncor(R) Inform(TM) HER-2/neu Gene Detection System. The Oncor(R) INFORM(TM) HER-2/neu Gene Detection System is a fluorescence in situ hybridization (FISH) DNA probe assay that determines the qualitative presence of HER-2/neu gene amplification on formalin-fixed, paraffin-embedded human breast tissue as an aid to stratify breast cancer patients according to risk for recurrence or disease-related death. It is indicated for use as an adjunct to existing clinical and pathologic information currently used as prognostic indicators in the risk stratification of breast cancer in patients who have had a priary, invasive, localized breast carcinoma and who are lymph node-negative.|22|1
67|P980024|null|PATHVYSION HER-2 DNA PROBE KIT|system, test, her-2/neu, nucleic acid or serum|1998-06-16 00:00:00|1998-12-11 00:00:00|false|true|Approval for the PathyVysion(TM) HER-2 DNA Probe Kit. The PathyVysion(TM) HER-2 DNA Probe Kit (PathyVysion Kit) is designed to detect amplification ofthe HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded human breast cancer tissue speciments. Results from the PathVysion Kit are intended for use as an adjuncto to existing clinical and pathologic information currently used as prognostic factors in state II, node-positive breast cancer patients. The PathVysion Kit is further indicated as an aid in predct disease-free and overall survival in patients with stage II, node positive breast cancer treated with adjuvant cyclophosphamide, dosorubicin, and 5-fluorouracil (CAF) chemotherapy.|23|1
68|P990081|S019|PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-05-06 00:00:00|2013-07-25 00:00:00|false|true|APPROVAL FOR MINOR MODIFICATIONS TO THE DESIGN OF THE DISPENSER INWHICH THE PMA REAGENTS IN THE DEVICES ARE STORED AND OR USED, INCLUDING A CHANGE IN THE MATERIALS THE VARIOUS DISPENSER PARTS ARE MADE FROM.|24|1
69|P990081|S015|PATHWAY ANTI-HER2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-01-14 00:00:00|2013-03-20 00:00:00|false|true|APPROVAL FOR A CHANGE FROM FLUORINATED BOTTLES TO NON-FLUORINATED BOTTLES FOR STORAGE OF THE GENERAL PURPOSE REAGENTS USED IN THE STAINING WITH THE PATHWAY AND ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY.|24|1
70|P990081|S016|PATHWAY ANTI-HER-2 (4B) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-03-04 00:00:00|2013-04-02 00:00:00|false|true|ADD AN ALTERNATE QUALIFIED SUPPLIER FOR SUBASSEMBLIES USED IN THE PRODUCTION OF THE BENCHMARK ULTRA AND BENCHMARK XT INSTRUMENTS, CRITICAL COMPONENTSUSED IN THE MANUFACTURE OF THE SUBJECT REAGENTS.|24|1
71|P990081|S013|PATHWAY HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2012-07-27 00:00:00|2012-08-09 00:00:00|false|true|ADDITION OF A SUPPLIER OF RAW MATERIALS FOR THE IVIEW DETECTION KIT, WHICH IS PARTOF THE DEVICE.|24|1
72|P990081|S014|PATHWAY ANTI-HER -2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2012-08-31 00:00:00|2012-11-14 00:00:00|false|true|APPROVAL FOR IMPLEMENTING A CHANGE TO THE VENTANA REGENT DISPENSER SEAL FOR THE BENCHMARK AUTOMATED STAINING INSTRUMENTS.|24|1
73|P990081|S001|PATHWAY HER 2 (CLONE CB11)|system, test, her-2/neu, ihc|2002-08-20 00:00:00|2002-11-27 00:00:00|false|true|APPROVAL FOR A NEW MANUFACTURING SITE LOCATED AT VENTANA MEDICAL SYSTEMS, TUCSON, ARIZONA.|24|1
74|P990081|S002|PATHWAY HER-2/NEU (CLONE CD11) PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2005-09-06 00:00:00|2005-10-21 00:00:00|false|true|APPROVAL OF LABELING CHANGES FOR THE PATHWAY HER-2/NEU (CLONE CD11) IN THE "INTENDED USE" SECTION, ADDITION OF AN "OPTIONAL EQUIPMENT NOT PROVIDED" SECTION AND CHANGES TO THE "PRINCIPLES AND PROCEDURES" SECTION TO REFLECT THE ADDITION OF TRIPATH IMAGING VIAS INSTRUMENT TO BE USED IN CONJUNCTION WITH THE VENTANA PATHWAY HER 2 ASSAY AS AN OPTIONAL ACCESSORY. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE SAME TRADE NAME PATYHWAY HER-2/NEU (CLONE CD11) AND IS INDICATED: VENTANA MEDICAL SYSTEMS, INC.'S (VENTANA) PATHWAY HER 2 (CLONE CD11) IS A MOUSE MONOCLONAL ANTIBODY INTENDED FOR LABORATORY USE FOR THE SEMI-QUANTITATIVE DETECTION OF C-ERBB2- ANTIGEN IN SECTIONS OF FORMALIN FIXED, PARAFFIN EMBEDDED NORMAL AND NEOPLASTIC TISSUE ON A VENTANA AUTOMATED IMMUNOHISTOCHEM-ISTRY SLIDE STAINING DEVICE. IT IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST CANCER PATIENTS FOR WHOM HERCEPTIN TREATMENT IS CONSIDERED. NOTE: ALL OF THE PATIENTS IN THE HERCEPTIN CLINICAL TRIALS WERE SELECTED USING A CLINICAL TRIAL ASSAY. NONE OF THE PATIENTS IN THOSE TRIALS WERE SELECTED USING PATHWAY HER 2. THE PATHWAY HER 2 WAS COMPARED TO THE DAKO HERCEPTEST ON AN INDEPENDENT SAMPLE AND FOUND TO PROVIDE ACCEPTABLY CONCORDANT RESULTS. THE ACTUAL CORRELATION OF PATHWAY HER 2 TO CLINICAL OUTCOME HAS NOT BEEN ESTABLISHED. THE VENTANA IMAGE ANALYSIS SYSTEM (VIAS) IS ADJUNCTIVE OPTIONAL COMPUTER-ASSISTED IMAGE ANALYSIS SYSTEM FUNCTIONALLY CONNECTED TO AN INTERACTIVE MICROSCOPE. IT IS INTENDED FOR USE AS AN AID TO THE PATHOLOGIST IN THE DETECTION CLASSIFICATION AND COUNTING OF CELLS OF INTEREST BASED ON MARKET INTENSITY, SIZE AND SHAPE USING APPROPRIATE CONTROLS TO ASSURE THE VALIDITY OF THE VIAS SCORES.|24|1
75|P990081|S006|PATHWAY HER-2/NEU CONTROL SLIDES|system, test, her-2/neu, ihc|2007-06-27 00:00:00|2007-07-24 00:00:00|false|true|CHANGE IN ACCEPTANCE TESTING FOR THE CONTROL SLIDE LOT RELEASE TESTING.|24|1
76|P990081|S007|PATHWAY ANTI-HER-2/NEU|system, test, her-2/neu, ihc|2007-11-19 00:00:00|2007-12-12 00:00:00|false|true|CHANGE IN THE RAW MATERIAL USED TO MANUFACTURE CELL LINE MULTIBLOCKS TO ELIMINATE BACKGROUND STAINING OF THE CONTROL SLIDES.|24|1
77|P990081|S003|PATHWAY ANTI-HER-2/NEU (4B5) PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2006-05-04 00:00:00|2007-01-11 00:00:00|false|true|APPROVAL FOR MODIFICATIONS TO THE PATHWAY C-ERBB-2 PRIMARY ANTIBODY(CLONE CB11) WHICH INCLUDE 1) CHANGE THE PRIMARY ANTIBODY FROM THE MOUSE MONOCLONAL ANTIBODY CB11 TO THE RABBIT MONOCLONAL ANTIBODY 4B5, 2) CHANGE THE DETECTION FORMAT FROM BASIC DAB DETECTION KIT TO THE VENTANA MEDICAL SYSTEMS IVIEW DAB DETECTION KIT, 3) ADD THE OPTIONAL ULTRAVIEW UNIVERSAL DAB DETECTION KIT FOR BIOTIN FREE DETECTION FORMAT, 4) CONSOLIDATE LEVEL 1,3 AND NEGATIVE HER-2 ASSAY CONTROL SLIDES ONTO A SINGLE SLIDE AND ADD A LEVEL 2 ASSAY CONTROL AND THE CONTROL WILL BE MARKETED UNDER THE TRADE NAME OF PATHWAY HER2 4 IN 1 CONTROL SLIDE, AND 5) INCLUDE THE VENTANA IMAGE ANALYSIS SYSTEM (VIAS) IN THE LABELING. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME PATHWAY ANTI-HER-2/NEU (4B5) PRIMARY ANTIBODY AND IS INDICATED FOR: VENTANA MEDICAL SYSTEMS, INC.?S (VENTANA) PATHWAY ANTI-HER-2/NEU (4B5) PRIMARY ANTIBODY (PATHWAY HER2 (4B5)) IS A RABBIT MONOCLONAL ANTIBODY INTENDED FOR LABORATORY USE FOR THE SEMI-QUANTITATIVE DETECTION OF HER2 ANTIGEN IN SECTIONS OF FORMALIN-FIXED, PARAFFIN-EMBEDDED NORMAL AND NEOPLASTIC TISSUE ON A VENTANA AUTOMATED IMMUNOHISTOCHEMISTRY SLIDE STAINING DEVICE. IT IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST CANCER PATIENTS FOR WHOM HERCEPTIN TREATMENT IS BEING CONSIDERED.|24|1
78|P990081|S026|PATHWAY ANTI-HER-2/NEU (4B) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2014-01-06 00:00:00|2014-01-23 00:00:00|false|true|ADDITION OF A NEW SUPPLIER FOR A SUBASSEMBLY USED IN THE MANUFACTURE OF THE BENCHMARK XT INSTRUMENT.|24|1
79|P990081|S021|PATHWAY HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-07-30 00:00:00|2013-08-22 00:00:00|false|true|ADD A SUPPLIER (FEF CHEMICALS) OF A RAW MATERIAL (RECOMBINANT HUMAN INSULIN) FOR THE BD CELL MAB MEDIA BASE AND TO BRING THE FORMULATION OF THIS MEDIA FROM BECTON DICKINSON INTO IN-HOUSE PRODUCTION AT VENTANA MEDICAL SYSTEMS, INC., IN TUCSON, ARIZONA.|24|1
80|P990081|S028|PATHWAY ANTI-HER-2/NEU (4B) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2014-02-06 00:00:00|2014-05-06 00:00:00|false|true|APPROVAL FOR A NEW ADHESIVE FOR THE SLIDE HEATERS ON THE BENCHMARK XT AND ULTRA AUTOMATED SLIDE STAINERS.|24|1
81|P990081|S022|PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-08-30 00:00:00|2013-10-02 00:00:00|false|true|ADD A SUPPLIER (ROCHE, PENZBERG) OF A COMPONENT (STREPTAVIDIN HORSERADISH PEROXIDASE) FOR THE IVIEW DAB DETECTION KIT.|24|1
82|P990081|S027|PATHWAY ANTI-HER-2/NEU (4B) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2014-01-22 00:00:00|2014-04-09 00:00:00|false|true|APPROVAL FOR ADDITION OF A CURRENT SENSE PRINTED CIRCUIT BOARD (PCB) TO THE BENCHMARK ULTRA INSTRUMENT THAT WILL PREVENT AN OVERCURRENT SITUATION.|24|1
83|P990081|S039|PATHWAY Anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody|system, test, her-2/neu, ihc|2019-02-13 00:00:00|2019-05-03 00:00:00|false|true|Approval for the Ventana Medical Systems, Inc.'s (Ventana) PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY HER2 (4B5)) is a rabbit monoclonal antibody intended for laboratory use for the semi-quantitative detection of HER2 antigen in sections of formalin-fixed, paraffin-embedded normal and neoplastic tissue following staining on a BenchMark XT or BenchMark ULTRA instrument. It is indicated as an aid in the assessment of breast cancer patients for whom HerceptinÂ® (trastuzumab) or KADCYLAÂ® (ado-trastuzumab emtansine) treatment is being considered.Note: All of the patients in the Herceptin clinical trials were selected using a clinical trial assay. None of the patients in those trials were selected using PATHWAY anti-HER-2/neu (4B5). PATHWAY anti-HER-2/neu (4B5) was compared to PATHWAY HER-2 (clone CB11) Primary Antibody on an independent sample set and found to provide acceptably concordant results. The actual correlation of PATHWAY anti-HER-2/neu (4B5) to clinical outcome has not been established.This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.This antibody is intended for in vitro diagnostic (IVD) use.|24|1
84|P990081|S024|PATHWAY ANTI-HER2/NEU (4B5)RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-11-12 00:00:00|2013-12-16 00:00:00|false|true|ADDITION OF A NEW SUPPLIER FOR A PCBA USED IN THE MANUFACTURE OF THE BENCHMARK XT INSTRUMENT.|24|1
85|P990081|S017|PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-03-12 00:00:00|2013-07-23 00:00:00|false|true|APPROVAL FOR MODIFICATIONS IN DESIGN TO PREVENT WASTE SYSTEM OVERFLOW OR OTHER LEAKS FROM CAUSING SHORTING CONDITIONS WITH THE BENCHMARK ULTRAS INTERNAL CIRCUITS.|24|1
86|P990081|S018|PATHWAY ANTI-HER-2/NEU (4B5)RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-04-17 00:00:00|2013-05-13 00:00:00|false|true|ADDITION OF A NEW SUPPLIER OF PRINTED CIRCUIT BOARD ASSEMBLIES USED IN THE PRODUCTION OF THE BENCHMARK ULTRA AND BENCHMARK XT INSTRUMENTS.|24|1
87|P990081|null|PATHWAY ANTI-HCR-2/NCU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|1999-12-13 00:00:00|2000-11-28 00:00:00|false|true|APPROVAL FOR THE PATHWAY(TM) HER 2 (CLONE CB11). THE DEVICE IS A MOUSE MONOCLONAL ANTIBODY INTENDED FOR LABORATORY USE FOR THE SEMI-QUANTITATIVE DETECTION OF C-ERBB-2 ANTIGEN IN SECTIONS OF FORMALIN FIXED, PARAFFIN EMBEDDED NORMAL AND NEOPLASTIC TISSUE ON A VENTANA AUTOMATED IMMUNOHISTOCHEMISTRY SLIDE STAINING DEVICE. IT IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST CANCER PATIENTS FOR WHOM HERCEPTIN(R) TREATMENT IS BEING CONSIDERED.|24|1
88|P990081|S005|VENTANNA PATHWAY HER-2 (CLONE CB11)|system, test, her-2/neu, ihc|2007-03-02 00:00:00|2007-04-11 00:00:00|false|true|APPROVAL FOR CHANGE IN THE LABELING TO INCLUDE THE PATHWAY HER-2 4 IN 1 CONTROL SLIDES.|24|1
89|P990081|S008|PATHWAY ANTI-HER 2INEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2010-10-21 00:00:00|2010-11-17 00:00:00|false|true|APPROVAL FOR CHANGES IN QUALITY CONTROLS TO ENSURE THE SAFETY IN THE USE OF THE DEVICE BY: 1) ADDING A TEST TO ENSURE APPROPRIATE STAIN INTENSITY OF THE PRIMARY ANTIBODY AT THE BULK MANUFACTURING STAGES; AND 2) ADDING A QUALITY CONTROL TESTING STEPS AT THE RAW MATERIAL PRODUCTION AND BULK MANUFACTURING STAGES.|24|1
90|P990081|S023|PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-10-28 00:00:00|2013-11-15 00:00:00|false|true|AUTOMATION OF TESTING PROCESSES (CURRENTLY PERFORMED SEMI-MANUALLY) USING THE NEW AUTOMATED DISPENSER VERIFICATION MODULE (DVM).|24|1
91|P990081|S010|PATHWAY ANTI-HER-2/NEU (4B5) RABBITT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2011-01-03 00:00:00|2011-09-06 00:00:00|false|true|APPROVAL FOR THE PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY ASSAY MIGRATION TO THE BENCHMARK ULTRA AUTO STAINER, CHANGES TO PATHWAY HER-24 IN 1 CONTROL SLIDES, AND MINOR SOFTWARE UPDATES (VSS 11.7 TO 11.8).|24|1
92|P990081|S020|PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-05-07 00:00:00|2013-10-25 00:00:00|false|true|APPROVAL FOR ADDITION OF A NEW SUPPLIER OF BIOCONJUGATES FOR THE ULTRAVIEW UNIVERSAL DAB DETECTION KIT. THE DETECTION KIT IS PART OF THE PATHWAY ANTI-HER 2/NEU RABBIT MONOCLONAL PRIMARY ANTIBODY (4B5).|24|1
93|P990081|S011|PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2011-05-23 00:00:00|2011-09-27 00:00:00|false|true|APPROVAL FOR THE ADDITION OF A STRAINER TYPE BARRIER TO THE CURRENT DAB DISPENSER RETAINER DESIGN, COLORIZATION OF STOP BARREL, AND ASSEMBLY EQUIPMENT UPDATES TO ACCOMMODATE THE MODIFIED RETAINER.|24|1
94|P990081|S025|PATHWAY ANTI-HER-2/NEW (4B5)RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2013-12-27 00:00:00|2014-01-22 00:00:00|false|true|ADDITION OF A NEW SUPPLIER FOR PCBAS (PRINTED CIRCUIT BOARD ASSEMBLIES) USED IN THE MANUFACTURE OF THE BENCHMARK ULTRA INSTRUMENT.|24|1
95|P990081|S012|PATWAY HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2012-07-25 00:00:00|2012-08-21 00:00:00|false|true|APPROVAL FOR AN EXTENSION OF SHELF LIFE OF THE IVIEW DAB DETECTIONKIT AND THE ULTRAVIEW DAB DETECTION KIT FOR THE PATHWAY ANTI-HER-2/NEU (4B5) RABBIT MONOCLONAL PRIMARY ANTIBODY.|24|1
96|P990081|S004|PATHWAY HER-2/NEU (CLONE CB11) PRIMARY ANTIBODY|system, test, her-2/neu, ihc|2006-08-28 00:00:00|2006-09-05 00:00:00|false|true|CHANGE TO ELIMINATE THE REQUIREMENT FOR FINAL ACCEPTANCE TESTING OF ANTI-C-ERBB-2 (CLONECB11) ON TWO INSTRUMENT SYSTEMS.|24|1
97|P040030|null|INSITE HER-2/NEU KIT|system, test, her-2/neu, ihc|2004-06-22 00:00:00|2004-12-22 00:00:00|false|true|APPROVAL FOR THE INSITE HER-2/NEU KIT. THE DEVICE IS INDICATED FOR: INSITE HER-2/NEU MOUSE MONOCLONAL ANTIBODY (CLONE CB11) KIT IS INTENDED FOR IN VITRO DIAGNOSTIC USE IN IMMUNOHISTOCHEM-ISTRY (IHC) ASSAYS TO SEMI-QUANTITATIVELY LOCALIZED BY LIGHT MICROSCOPY THE OVER-EXPRESSION OF HER-2/NEU (I.E., C-ERBB-2) IN FORMALIN-FIXED, PARAFFIN-EMBEDDED NORMAL AND NEOPLASTIC TISSUE SECTIONS. INSITE HER-2/NEU IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST CANCER PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) THERAPY IS BEING CONSIDERED. CLINICAL INTERPRETATION OF INSITE HER-2/NEU IMMUNOSTAINING RESULTS (ABSENCE OR PRESENCE; SEMI-QUANTITATIVE INTENSITY SCORE) SHOULD BE COMPLEMENTED BY APPROPRIATE CONTROLS AND MORPHOLOGICAL TISSUE ANALYSIS AND BE EVALUATED BY A QUALIFIED PATHOLOGIST WITHIN THE CONTEXT OF PATIENT CLINICAL HISTORY AND OTHER DIAGNOSTIC RESULTS.|25|1
98|P050040|S002|SPOT-LIGHT HER2 CISH KIT|chromogenic in situ hybridization, nucleic acid amplification, her2/neu gene, breast cancer|2011-03-01 00:00:00|2011-04-29 00:00:00|false|true|APPROVAL FOR CHANGES IN THE PRODUCT INSERT: 1) MANUFACTURING ADDRESS CHANGE; 2) COPYRIGHT CHANGE FROM INVITROGEN CORPORATION TO LIFE TECHNOLOGIES. INVITROGEN WILL REMAIN THE BRAND NAME AND THEREFORE IS STILL INCLUDED ON THE PRODUCT INSERT AND LABELING; AND AN ADDITION OF LITERATURE REFERENCES TO THE BIBLIOGRAPHY. |26|1
99|P050040|S003|SPOT-LIGHT HER2 CISH KIT|chromogenic in situ hybridization, nucleic acid amplification, her2/neu gene, breast cancer|2012-06-01 00:00:00|2012-07-06 00:00:00|false|true|EXTENSION OF THE EXPIRATION DATE FOR A SINGLE LOT OF HER-2 SPT DNA TEMPLATE (LOT 63013).|26|1
100|P050040|S001|SPOT-LIGHT HER2 CISH KIT|chromogenic in situ hybridization, nucleic acid amplification, her2/neu gene, breast cancer|2011-02-03 00:00:00|2011-07-12 00:00:00|false|true|APPROVAL FOR A MANUFACTURING SITE LOCATED IN FREDERICK, MARYLAND.|26|1
101|P090015|null|BOND ORACLE HER2 IHC SYSTEM|system, test, her-2/neu, ihc|2009-07-22 00:00:00|2012-04-18 00:00:00|false|true|APPROVAL FOR THE BOND ORACLE HER2 IHC SYSTEM. THIS DEVICE IS INDICATED FOR: BOND ORACLE HER2 IHC SYSTEM IS A SEMI-QUANTITATIVE IMMUNOHISTOCHEMICAL (IHC) ASSAY TO DETERMINE HER2 (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) ONCOPROTEIN STATUS IN FORMALIN-FIXED, PARRAFIN EMBEDDED BREAST CANCER TISSUE PROCESSED FOR HISTOLOGICAL EVALUATION FOLLOWING AUTOMATED STAINING ON THE BOND-MAX SLIDE STAINING INSTRUMENT. THE BOND ORACLE HER2 IHC SYSTEM IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED.|27|1
102|P100024|null|HER2 CISH PHARMDX KIT|chromogenic in situ hybridization, nucleic acid amplification, her2/neu gene, breast cancer|2010-06-21 00:00:00|2011-11-30 00:00:00|false|true|APPROVAL FOR THE HER2 CISH PHARMDX KIT. THIS DEVICE IS INDICATED TOR;HER2 CISH PHARMDX KIT IS INTENDED FOR DUAL-COLOR CHROMOGENIC VISUALIZATION OF SIGNALS ACHIEVED WITH DIRECTLY LABELED IN SITU HYBRIDIZATION PROBES TARGETING THE HER2 GENE AND CENTROMERIC REGION OF CHROMOSOME 17. THE KIT IS DESIGNED TO QUANTITATIVELY DETERMINE HER2 GENE STATUS IN FORMALIN-FIXED, PARAFFIN-EMBEDDED BREAST CANCER TISSUE SPECIMENS. RED AND BLUE CHROMOGENIC SIGNALS ARE GENERATED ON THE SAME TISSUE SECTION FOR EVALUATION UNDER BRIGHT FIELD MICROSCOPY. THE CISH PROCEDURE IS AUTOMATED USING DAKO AUTOSLAINERINSTRUMENTS. HER2 CISH PHARMDX KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED. RESULTS FROM THE HER2 CISH PHARMDX KIT ARE INTENDED FOR USE AS AN ADJUNCT TO THE CLINICOPATHOLOGIC INFORMATIONCURRENTLY USED FOR ESTIMATING PROGNOSIS IN STAGE II, NODE-POSITIVE BREAST CANCER PATIENTS.|28|1
103|P100027|S030|INFORM HER2 Dual ISH DNA Probe Cocktail assays|chromogenic in situ hybridization, nucleic acid amplification, her2/neu gene, breast cancer|2019-02-13 00:00:00|2019-05-03 00:00:00|false|true|Approval for the Ventana Medical Systems, Incâ€™s (Ventana) INFORM HER2 Dual ISH DNA Probe Cocktail is intended to determine HER2 gene status by enumeration of the ratio of the HER2 gene to Chromosome 17. The HER2 and Chromosome 17 probes are detected by light microscopy using two color chromogenic in situ hybridization (ISH) in formalin-fixed, paraffin-embedded human breast cancer tissue specimens following staining on a BenchMark XT or BenchMark ULTRA instrument. The INFORM HER2 Dual ISH DNA Probe Cocktail is indicated as an aid in the assessment of breast cancer patients for whom HerceptinÂ® (trastuzumab) or KADCYLAÂ® (ado-trastuzumab emtansine) treatment is being considered. This product should be interpreted by a qualified reader in conjunction with histological examination, relevant clinical information, and proper controls.This reagent is intended for in vitro diagnostic (IVD) use.|29|1
104|P100027|null|INFORM HER2 DUAL ISH DNA PROBE COCKTAIL|chromogenic in situ hybridization, nucleic acid amplification, her2/neu gene, breast cancer|2010-07-12 00:00:00|2011-06-14 00:00:00|false|true|APPROVAL FOR THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL. THIS DEVICE IS INDICATED FOR:THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL IS INTENDED FOR USE IN DETERMINING HER2 GENE STATUS BY ENUMERATION OF THE RATIO OF THE HER2 GENE TO CHROMOSOME 17. THE HER2 AND CHROMOSOME 17 PROBES ARE DETECTED USING TWO COLOR CHROMOGENIC IN SITU HYBRIDIZATION (ISH) IN FORMALIN-FIXED. PARAFFIN-EMBEDDED HUMAN BREAST CANCER TISSUE SPECIMENS FOLLOWING STAINING ON VENTANA BENCHMARK XT AUTOMATED SLIDE STAINERS (USING NEXES SOFTWARE), BY LIGHT MICROSCOPY. THE INFORM HER2 DUAL ISH DNA PROBE COCKTAIL IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM I-HERPCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED.THIS PRODUCT SHOULD BE INTERPRETED BY A QUALIFIED READER IN CONJUNCTION WITH HISTOLOGICAL EXAMINATION, RELEVANT CLINICAL INFORMATION, AND PROPER CONTROLS.THIS REAGENT IS INTENDED FOR IN VITRO DIAGNOSTIC (IVD) USE.|29|1
105|P980018|null|DAKO HERCEPTEST|system, test, her-2/neu, ihc|1998-05-18 00:00:00|1998-09-25 00:00:00|false|true|Approval for the DAKO Herceptest. This device is a semi-quantitative immunohistochemical assay to determine HER2 overexpression in breast cancer tissues routinely processed for histological evaluation. HercepTest is indicated as an aid in the assessment of patients for whom HERCEPTIN(R)(Transtuzumab) treatment is being considered.|30|1
106|P980018|S018|HERCEPTEST|system, test, her-2/neu, ihc|2013-11-21 00:00:00|2013-11-26 00:00:00|false|true|APPROVAL FOR LABELING CHANGES MADE TO ENHANCE SAFETY OF HERCEPTEST. WHEN USED FOR GASTRIC AND GASTROESOPHAGEAL CANCER INDICATIONS.|30|1
107|P040005|null|DAKOCYTOMATION HER2 FISH PHARMDX KIT|system, test, her-2/neu, nucleic acid or serum|2004-01-29 00:00:00|2005-05-03 00:00:00|false|true|APPROVAL FOR THE DAKOCYTOMATION HER2 FISH PHARMDX KIT. THE DEVICE IS INDICATED FOR: THE DAKOCYTOMATION HER2 FISH PHARMDX KIT IS A DIRECT FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ASSAY DESIGNED TO QUANTITATIVELY DETERMINE THE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED, PARAFFIN-EMBEDDED BREAST CANCER TISSUE SPECIMENS. HER2 FISH PHARMDX KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED. RESULTS FORM THE HER2 FISH PHARMDX KIT ARE INTENDED FOR USE AS AN ADJUNCT TO THE CLINICOPATHOLOGIC INFORMATION CURRENTLY USED FOR ESTIMATING PROGNOSIS IN STAGE II, NODE POSITIVE BREAST CANCER PATIENTS.|31|1
108|P040005|S005|HER2 FISH PHARMDX KIT|system, test, her-2/neu, nucleic acid or serum|2010-04-20 00:00:00|2010-10-20 00:00:00|false|true|APPROVAL FOR THE HER2 FISH PHARMDX KIT. THE DEVICE IS INDICATED FOR IN VITRO DIAGNOSTIC USE. THE HER2 FISH PHARMDX KIT IS A DIRECT FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ASSAY DESIGNED TO QUANTITATIVELY DETERMINE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) BREAST CANCER TISSUE SPECIMENS AND FFPE SPECIMENS FROM PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA. HER2 FISH PHARMDX KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED (SEE HERCEPTIN PACKAGE INSERT).|31|1
109|P040005|S006|HER2 FISH PHARMADX KIT|system, test, her-2/neu, nucleic acid or serum|2011-12-05 00:00:00|2012-06-08 00:00:00|false|true|APPROVAL FOR ADDITION OF PERTUZUMAB IN THE LABELING OF HER2 FISH PHARMDX KIT. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME HER2 FISH PHARMDX KIT AND ITS INDICATION FOR USE IS: A DIRECT FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ASSAY DESIGNED TOQUANTITATIVELY DETERMINE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) BREAST CANCER TISSUE SPECIMENS AND FFPE SPECIMENS FROM PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA. HER2 FISH PHARMDX KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF BREAST AND GASTRIC CANCER PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED AND FOR BREAST CANCER PATIENTS FOR WHOM PERJETA (PERTUZUMAB) TREATMENT IS BEING CONSIDERED (SEE HERCEPTIN AND PERJETA PACKAGE INSERTS).|31|1
110|P040005|S009|HER2 FISH PHARMADX KIT|system, test, her-2/neu, nucleic acid or serum|2012-08-24 00:00:00|2013-02-22 00:00:00|false|true|APPROVAL FOR ADDITION OF KADCYLA (ADO-TRASTUZUMAB EMTANSINE) IN THE LABELING OF HER2 IQ-FISH PHARMDX KIT.|31|1
111|P120014|null|BIOMERIEUX THXID BRAF ASSAY KIT|somatic gene mutation detection system|2012-07-31 00:00:00|2013-05-29 00:00:00|false|true|APPROVAL FOR THE THXID BRAF KIT FOR USE ON THE ABI 7500 FAST DX REAL-TIME PCR INSTRUMENT. THIS DEVICE IS INDICATED FOR: THE THXID BRAF KIT IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION OF THE BRAF V600E AND V600K MUTATIONS IN DNA SAMPLES EXTRACTED FROM FORMALIN-FIXED PARAFFINEMBEDDED (FFPE) HUMAN MELANOMA TISSUE. THE THXID BRAF KIT IS A REAL-TIME PCR TEST ON THE ABI 7500 FAST DX SYSTEM AND IS INTENDED TO BE USED AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E MUTATION FOR TREATMENT WITH DABRAFENIB [TAFINLARÂ®] AND AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E OR V600K MUTATION FOR TREATMENT WITH TRAMETINIB [MEKINIST].|32|1
112|P110012|null|VYSIS ALK BREAK APART FISH PROBE KIT, VYSIS PARAFFIN PRETREATMENT IV & POST HYBRIDIZATION WASH BUFFER KIT PROBECHEK ALK|fluorescence in situ hybridization, anaplastic lymphoma kinase, gene rearrangement|2011-04-01 00:00:00|2011-08-26 00:00:00|false|true|APPROVAL FOR THE VYSIS ALK BREAK APART FISH PROBE KIT; VYSIS PARAFFIN PRETREATMENT IV & POST HYBRIDIZATION WASH BUFFER KIT; PROBECHEK ALK NEGATIVE CONTROL SLIDES; AND PROBECHEK ALK POSITIVE CONTROL SLIDES. THIS DEVICE IS INDICATED FOR: THE VYSIS ALK BREAK APART FISH PROBE KIT IS A QUALITATIVE TEST TO DETECT REARRANGEMENTS INVOLVING THE ALK GENE VIA FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN FORMALIN-FIXED PARAFFIN -EMBEDDED (FFPE) NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE SPECIMENS TO AID IN IDENTIFYING THOSE PATIENTS ELIGIBLE FOR TREATMENT WITH XALKORI CRIZOTINIB). THE TEST IS FOR PRESCRIPTION USE ONLY. THE VYSIS PARAFFIN PRETREATMENT IV & POST HYBRIDIZATION WASH BUFFER KIT IS USED TO PREPARE PARAFFIN-EMBEDDED LUNG CANCER TISSUE SECTIONS FIXED ON POSITIVELY CHARGED SLIDES FOR USE IN FLUORESCENCE IN SITU HYBRIDIZATION (FISH) WITH VYSIS DNA FISH PROBES.THE PROBECHEK ALK NEGATIVE CONTROL SLIDES ARE INTENDED FOR USE AS AN ASSAY CONTROL FOR APPROPRIATE HYBRIDIZATION CONDITIONS DURING ROUTINE USE OF THE VYSIS ALK BREAK APART FISH PROBE KIT (LIST NO. 06N38-020). THE PROBECHEK ALK NEGATIVE CONTROL SLIDES SHOULD BE ASSAYED IN CONJUNCTION WITH THE USER'S SPECIMEN SLIDES ACCORDING THE PACKAGE INSERT FOR THE VYSIS ALK BREAK APART FISH PROBE KIT (LIST NO. 06N38-020). THE PROBECHEK ALK POSITIVE CONTROL SLIDES ARE INTENDED FOR USE AS AN ASSAY CONTROL FOR APPROPRIATE HYBRIDIZATION CONDITIONS DURING ROUTINE USE OF THE VYSIS ALK BREAK APART FISH PROBE KIT (LIST NO. 06N38-020). THE PROBECHEK ALK POSITIVE CONTROL SLIDES SHOULD BE ASSAYED IN CONJUNCTION WITH THE USER'S SPECIMEN SLIDES ACCORDING THE PACKAGE INSERT FOR THE VYSIS ALK BREAK APART FISH PROBE KIT (LIST NO. 06N38-020).|33|1
113|P110012|S020|Vysis ALK Break Apart Fish Probe Kit|fluorescence in situ hybridization, anaplastic lymphoma kinase, gene rearrangement|2019-12-23 00:00:00|2020-05-22 00:00:00|false|true|Approval of the expansion of the Indications for Use for the Vysis ALK Break Apart FISH Probe Kit to include an indication for ALUNBRIGÂ® (brigatinib). The device, as modified, will be marketed under the trade name Vysis ALK Break Apart FISH Probe Kit and is indicated for:INTENDED USE The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) tissue specimens from non-small cell lung cancer (NSCLC) patients.INDICATION FOR USEThe Vysis ALK Break Apart FISH Probe Kit is indicated as an aid in identifying patients eligible for treatment with XALKORIÂ® (crizotinib) and ALUNBRIGÂ® (brigatinib) in accordance with the approved therapeutic product labeling.|33|1
114|P110020|S016|Roche cobas DNA Sample Preparation Kit, COBAS 4800 BRAF V600 MUTATION TEST|somatic gene mutation detection system|2016-06-30 00:00:00|2016-11-07 00:00:00|false|true|Approval for the cobasÂ® 4800 BRAF V600 Mutation Test. The cobasÂ® 4800 BRAF V600 Mutation Test is an in vitro diagnostic device intended for the qualitative detection of BRAF V600E mutation in DNA extracted from formalin-fixed, paraffin-embedded human melanoma tissue. The cobasÂ® 4800 BRAF V600 Mutation Test is a real-time PCR test on the cobasÂ® 4800 System, and is intended to be used as an aid in selecting melanoma patients for treatment with the targeted therapies listed in the table below, in accordance with the approved therapeutic product labeling: Therapeutic Therapeutic Indication Test ResultZELBORAFÂ® (vemurafenib) BRAF V600E Mutation DetectedCOTELLICÂ® (cobimetinib), in combination with ZELBORAFÂ® (vemurafenib) BRAF V600E or V600K* Mutation Detected* *Due to cross-reactivity by the cobasÂ® 4800 BRAF V600 Mutation Test, the clinical trial for cobimetinib, in combination with vemurafenib, included some patients whose tumor carried the BRAF V600K mutation. |34|1
115|P110020|null|COBAS 4800 BRAF V600 MUTATION TEST|somatic gene mutation detection system|2011-04-25 00:00:00|2011-08-17 00:00:00|false|true|APPROVAL FOR THE COBAS 4800 BRAF V600 MUTATION TEST. THIS DEVICE IS INDICATED FOR: THE COBAS 4800 BRAF V600 MUTATION TEST IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION OF THE BRAF V600E MUTATION IN DNA EXTRACTED FROM FORMALIN-FIXED, PARAFFIN-EMBEDDED HUMAN MELANOMA TISSUE. THE COBAS 4800 BRAF V600 MUTATION TEST IS A REAL-TIME PCR TEST ON THE COBAS 4800 SYSTEM, AND IS INTENDED TO BE USED AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E MUTATION FOR TREATMENT WITH VEMURAFENIB.|34|1
116|P160002|S006|VENTANA PD-L1(SP142) CDX ASSAY|immunohistochemistry assay, antibody, programmed death-ligand 1|2018-06-14 00:00:00|2018-07-02 00:00:00|false|true|Approval for modifying the intended use of the VENTANA PD-L1(SP142). The VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma and non-small cell lung cancer (NSCLC) tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. Determination of PD-L1 status is indication-specific, and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.PD-L1 expression in >= 5% IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue is indicated as an aid in identifying urothelial carcinoma patients for treatment with TECENTRIQ (atezolizumab).PD-L1 expression in >= 50% TC or >= 10% IC determined by VENTANA PD-L1 (SP142) Assay in NSCLC tissue may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).See the TECENTRIQÂ® product label for PD-L1 expression cutoff values guiding therapy in specific clinical circumstances.This product is intended for in vitro diagnostic (IVD) use.|35|1
117|P160002|S009|VENTANA PD-L1(SP142) Assay.|immunohistochemistry assay, antibody, programmed death-ligand 1|2018-09-14 00:00:00|2019-03-08 00:00:00|false|true|Approval for VENTANA PD L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD L1 clone SP142. The device is intended for use in the assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in the formalin-fixed, paraffin-embedded (FFPE) tissues indicated below stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. Determination of PD-L1 status is indication-specific, and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.VENTANA PD-L1 (SP142) Assay is indicated as an aid for identifying patients for treatment with the therapies for the respective cutoffs listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1. Companion diagnostic indications for the VENTANA PD-L1 (SP142) Assay Indication for use Therapy Cutoff Urothelial Carcinoma TECENTRIQ >= 5% ICTriple-Negative Breast Carcinoma (TNBC) TECENTRIQ >= 1% ICPD-L1 expression in >= 50% TC or >= 10% IC determined by VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) patients may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls. This product is intended for in vitro diagnostic (IVD) use.|35|1
118|P160006|null|VENTANA PD-L1 (SP142) Assay|immunohistochemistry assay, antibody, programmed death-ligand 1|2016-02-22 00:00:00|2016-10-18 00:00:00|false|true|Approval for the VENTANA PD-L1 (SP142) Assay. This device is indicated for the following: VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma and non-small cell lung cancer (NSCLC) tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. Determination of PD-L1 status is indication-specific, and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.PD-L1 expression in 5% IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue is associated with increased objective response rate (ORR) in a non-randomized study of TECENTRIQ (atezolizumab).PD-L1 expression in 50% TC or 10% IC as detected by VENTANA PD-L1 (SP142) Assay in NSCLC may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).|35|1
119|P160002|null|VENTANA PD-L1(SP142) CDX ASSAY|immunohistochemistry assay, antibody, programmed death-ligand 1|2016-01-13 00:00:00|2016-05-18 00:00:00|false|true|Approval for the PD-L1(SP142) Assay. The device is indicated for the following: VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplifcation Kit on a VENTANA BenchMark ULTRA instrument. PD-L1 status is determined by the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity. PD-L1 expression in >= 5% IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue is associated with increased objective response rate (ORR) in a non-randomized study of TECENTRIQ (atezolizumab).|35|1
120|P180043|null|therascreen FGFR RGQ RT-PCR Kit|somatic gene mutation detection system|2018-11-08 00:00:00|2019-04-12 00:00:00|false|true|Approval for the THERASCREENÂ® FGFR RGQ PCR KIT. The Therascreen FGFR RGQ RT-PCR Kit is a real-time, reverse transcription PCR test for the qualitative detection of two point mutations in exon 7 [p.R248C (c.742C>T), p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3) in the fibroblast growth factor receptor 3 (FGFR3) gene in RNA samples derived from formalin-fixed paraffin-embedded (FFPE) urothelial tumor tissue. The test is indicated for use as an aid in identifying urothelial cancer (UC) patients who harbor these alterations and are therefore eligible for treatment with BALVERSA (erdafitinib). Specimens are processed using the RNeasy DSP FFPE Kit for manual sample preparation followed by reverse transcription and then automated amplification and detection on the Rotor-Gene Q MDx (US) instrument.|36|1
121|P190001|null|therascreen PIK3CA RGQ PCR Kit|somatic gene mutation detection system|2019-01-17 00:00:00|2019-05-24 00:00:00|false|true|Approval for the therascreen PIK3CA RGQ PCR Kit. The therascreen PIK3CA RGQ PCR Kit is a real-time qualitative PCR test for the detection of 11 mutations in the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) gene (Exon 7: C420R; Exon 9: E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and Exon 20: H1047L, H1047R, H1047Y) using genomic DNA (gDNA) extracted from formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue or circulating tumor DNA (ctDNA) from plasma derived from K2EDTA anticoagulated peripheral whole blood taken from patients with breast cancer. The test is intended to aid clinicians in identifying breast cancer patients who may be eligible for treatment with PIQRAYÂ® (alpelisib) based on a PIK3CA Mutation Detected result. Patients whose FFPE tissue or plasma specimen produces a positive therascreen PIK3CA RGQ PCR Kit test result for the presence of one or more PIK3CA mutations are eligible for treatment with PIQRAY (alpelisib). Patients whose plasma specimen produces a negative result using this test should be reflexed to testing with FFPE tumor tissue for the presence of PIK3CA mutations. FFPE tumor specimens are processed using the QIAamp DSP DNA FFPE Tissue Kit for manual sample preparation. K2EDTA anticoagulated whole peripheral venous blood plasma specimens are processed using the QIAamp DSP Circulating Nucleic Acid Kit for manual sample preparation. For both specimen types, the Rotor-Gene Q (RGQ) MDx (US) instrument is used for automated amplification and detection. The Kit is to be used by trained personnel in a professional laboratory environment.|37|1
122|P190004|null|therascreen PIK3CA RGQ PCR Kit|somatic gene mutation detection system|2019-02-15 00:00:00|2019-05-24 00:00:00|false|true|Approval for the therascreen PIK3CA RGQ PCR Kit. The therascreen PIK3CA RGQ PCR Kit is a real-time qualitative PCR test for the detection of 11 mutations in the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) gene (Exon 7: C420R; Exon 9: E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and Exon 20: H1047L, H1047R, H1047Y) using genomic DNA (gDNA) extracted from formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue or circulating tumor DNA (ctDNA) from plasma derived from K2EDTA anticoagulated peripheral whole blood taken from patients with breast cancer. The test is intended to aid clinicians in identifying breast cancer patients who may be eligible for treatment with PIQRAYÂ® (alpelisib) based on a PIK3CA Mutation Detected result. Patients whose FFPE tissue or plasma specimen produce a positive therascreen PIK3CA RGQ PCR Kit test result for the presence of one or more PIK3CA mutations are eligible for treatment with PIQRAY (alpelisib). Patients whose plasma specimens produces a negative result using this test should be reflexed to testing with FFPE tumor tissue for the presence of PIK3CA mutations.FFPE tumor specimens are processed using the QIAamp DSP DNA FFPE Tissue Kit for manual sample preparation. K2EDTA anticoagulated whole peripheral venous blood plasma specimens are processed using the QIAamp DSP Circulating Nucleic Acid Kit for manual sample preparation. For both specimen types, the Rotor-Gene Q (RGQ) MDx (US) instrument is used for automated amplification and detection. The Kit is to be used by trained personnel in a professional laboratory environment.|37|1
123|P190014|null|myChoice HRD CDx|cancer-related germline gene mutation detection system|2019-05-03 00:00:00|2019-10-23 00:00:00|false|true|Approval of Myriad myChoiceÂ® CDx. Myriad myChoiceÂ® CDx is a next generation sequencing-based in vitro diagnostic test that assesses the qualitative detection and classification of single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status for treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling.Table1---Tumor Type: Ovarian Cancer, Biomarker: Myriad HRD (defined as deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score), Therapy: ZejulaÂ® (niraparib)|38|1
124|P190014|S003|myChoice CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2020-02-11 00:00:00|2020-05-08 00:00:00|false|true|"Approval for Myriad myChoiceÂ® CDx to include a companion diagnostic indication for homologous recombination deficiency (HRD) in ovarian cancer patients who may benefit from maintenance treatment with LynparzaÂ® (olaparib)""."|38|1
125|P190026|null|therascreen BRAF V600E RGQ PCR Kit|somatic gene mutation detection system|2019-09-30 00:00:00|2020-04-15 00:00:00|false|true|Approval for the therascreen BRAF V600E RGQ PCR Kit. The therascreen BRAF V600E RGQ PCR Kit is a real-time PCR test for the qualitative detection of V600E mutations in the BRAF gene using genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) human colorectal cancer (CRC) tumor tissue. The therascreen BRAF V600E RGQ PCR Kit is an in vitro diagnostic device intended to be used as an aid in selecting patients with metastatic colorectal cancer (mCRC) whose tumors carry the BRAF V600E mutation for treatment with BRAFTOVI (encorafenib) in combination with cetuximab. The therascreen BRAF V600E RGQ PCR Kit is for use on the Rotor-Gene Q MDx (US) instrument. The therascreen BRAF V600E RGQ PCR Kit is intended for in vitro diagnostic use. |39|1
126|P150025|null|PD-L1 IHC 28-8 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2015-07-09 00:00:00|2015-10-09 00:00:00|false|true|APPROVAL FOR THE PD-L1 IHC 28-8 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING:1) PD-L1 IHC 28-8 PHARMDX IS A QUALITATIVE IMMUNOHISTO-CHEMICAL ASSAY USING MONOCLONAL RABBIT ANTI-PD-L1, CLONE 28-8 INTENDED FOR USE IN THE DETECTION OF PD-L1 PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48; 2) PD-L1 PROTEIN EXPRESSION IS DEFINED AS THE PERCENTAGE OF TUMOR CELLS EXHIBITING POSITIVE MEMBRANE STAINING AT ANY INTENSITY; AND3) PD-L1 EXPRESSION AS DETECTED BY PD-L1 IHC 28-8 PHARMDX IN NON-SQUAMOUS NSCLC MAY BE ASSOCIATED WITH ENHANCED SURVIVAL FROM OPDIVO (NIVOLUMAB).|40|1
127|P150025|S013|PD-L1 IHC 28-8 pharmDx|immunohistochemistry assay, antibody, programmed death-ligand 1|2019-12-16 00:00:00|2020-05-15 00:00:00|false|true|Approval application (PMA) supplement submitted to expand the indication for the PD-L1 IHC 28-8 pharmDx to include detection of PD-L1 protein in NSCLC patients for treatment with OPDIVOÂ® (nivolumab) in combination with YERVOYÂ® (ipilimumab). The device, as modified, will be marketed under the trade name PD-L1 IHC 28-8 pharmDx and is indicated for in vitro diagnostic use.PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial carcinoma (UC) tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity. Companion Diagnostic Indication Tumor Indication PD-L1 Expression Clinical Cut Off Intended UseNSCLC >=1% tumor cell expression PD-L1 IHC 28-8 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with OPDIVOÂ® (nivolumab) in combination with YERVOYÂ® (ipilimumab).PD-L1 expression (>=1% or ?5% or >=10% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC may be associated with enhanced survival from OPDIVOÂ®.PD-L1 expression (>=1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in SCCHN may be associated with enhanced survival from OPDIVOÂ®. PD-L1 expression (>=1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in UC may be associated with enhanced response rate from OPDIVOÂ®. See the OPDIVOÂ® and YERYOVÂ® product labels for specific clinical circumstances guiding PD-L1 testing.|40|1
128|P200014|null|cobas® EZH2 Mutation Test|somatic gene mutation detection system|2020-03-02 00:00:00|2020-06-18 00:00:00|false|true|Approval for The cobasÂ® EZH2 Mutation Test. The device is a real-time allele-specific PCR test for qualitative detection of single nucleotide mutations for Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene in DNA extracted from formalin fixed paraffin embedded (FFPE) human follicular lymphoma tumor tissue specimens. The cobasÂ® EZH2 Mutation Test is intended for the identification of follicular lymphoma patients with an EZH2 mutation for treatment with TAZVERIK (tazemetostat), in accordance with the approved therapeutic product labeling.|41|1
129|P190031|null|HER2 Dual ISH DNA Probe Cocktail|chromogenic in situ hybridization, nucleic acid amplification, her2/neu gene, breast cancer|2019-11-29 00:00:00|2020-07-28 00:00:00|false|true|Approval for the VENTANA HER2 Dual ISH DNA Probe Cocktail assay.|42|1
130|P200010|null|Guardant360 CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2020-02-10 00:00:00|2020-08-07 00:00:00|false|true|Approval order for Guardant360Â® CDx. Guardant360Â® CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs), insertions and deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes. Guardant360 CDx utilizes circulating cell-free DNA (cfDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). The test is intended to be used as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients who may benefit from treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1. Companion Diagnostic IndicationsIndication: Non-small cell lung cancer (NSCLC); Biomarker: EGFR exon 19 deletions, L858R, and T790M*; Therapy: TAGRISSOÂ® (osimertinib)A negative result from a plasma specimen does not assure that the patientâ€™s tumor is negative for genomic findings. NSCLC patients who are negative for the biomarkers listed in Table 1 should be reflexed to tissue biopsy testing for Table 1 biomarkers using an FDA-approved tumor tissue test, if feasible.*The efficacy of TAGRISSOÂ® (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Additionally, the test is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. The test is for use with patients previously diagnosed with cancer and in conjunction with other laboratory and clinical findings. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. Guardant360 CDx is a single-site assay performed at Guardant Health, Inc.|43|1
131|P200010|S001|Guardant360 CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2020-11-20 00:00:00|2021-05-21 00:00:00|false|true|Approval order for extending the label claim to include an indication for RYBREVANT (amivantamab) in non-small cell lung cancer patients with EGFR exon 20 insertions.|43|1
132|P200010|S002|Guardant360 CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2020-12-18 00:00:00|2021-05-28 00:00:00|false|true|Approval of Guardant360 CDx for expanding the indications for use to include the companion diagnostic claim to identify non-small cell lung cancer patients with KRAS G12C mutation for treatment with LUMAKRASTM (sotorasib). |43|1
133|P190032|S001|FoundationOne Liquid CDx (F1 Liquid CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2020-08-28 00:00:00|2021-07-15 00:00:00|false|true|Approval to include a companion diagnostic indication for detection of MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping in non-small cell lung cancer patients who may benefit from treatment with TABRECTA (capmatinib)|44|1
134|P200006|null|FoundationOne Liquid CDx (F1 Liquid CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2020-02-03 00:00:00|2020-10-26 00:00:00|false|true|Approval for FoundationOneÂ® Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions, insertions and deletions (indels) in 311 genes, including rearrangements in three (3) genes, and copy number alterations in three (3) genes. FoundationOneÂ® Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOneÂ® Liquid CDx cfDNA blood collection tubes included in the FoundationOneÂ® Liquid CDx Blood Sample Collection Kit. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in table 1 in accordance with the approved therapeutic product labeling.Table 1: Companion diagnostic indicationsTumor Type Biomarker(s) Detected TherapyNon-small cell lung cancer (NSCLC) EGFR Exon 19 deletions andEGFR Exon 21 L858R alteration IRESSAÂ® (gefitinib)TAGRISSOÂ® (osimertinib)TARCEVAÂ® (erlotinib) ALK Rearrangements ALECENSAÂ® (alectinib)Prostate cancer BRCA1, BRCA2 alterations RUBRACAÂ® (rucaparib)Ovarian Cancer BRCA1, BRCA2 alterations RUBRACAÂ® (rucaparib)Breast Cancer PIK3CA mutations C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y PIQRAYÂ® (alpelisib)Additionally, FoundationOneÂ® Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.A negative result from a plasma specimen does not mean that the patientâ€™s tumor is negative for genomic findings. Patients who are negative for the mutations listed in Table 1 should be reflexed to routine biopsy and their tumor mutation status confirmed using an FDA-approved tumor tissue test, if feasible.Genomic findings other than those listed in Table 1 of the intended use statement are not prescriptive or conclusive for labeled use of any specific therapeutic product. FoundationOneÂ® Liquid CDx is a single-site assay performed at Foundation Medicine, Inc. in Cambridge, MA.|44|1
135|P200016|null|FoundationOne Liquid CDx|next generation sequencing oncology panel, somatic or germline variant detection system|2020-03-09 00:00:00|2020-11-06 00:00:00|false|true|Approval for the FoundationOneÂ® Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions, insertions and deletions (indels) in 311 genes, including rearrangements in four (4) genes, and copy number alterations in three (3) genes. FoundationOneÂ® Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOneÂ® Liquid CDx cfDNA blood collection tubes included in the FoundationOneÂ® Liquid CDx Blood Sample Collection Kit. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1: Companion diagnostic indicationsTumor Type Biomarker(s) Detected TherapyNon-small cell lung cancer (NSCLC) ALK Rearrangements ALECENSAÂ® (alectinib) EGFR Exon 19 deletions andEGFR Exon 21 L858R alteration IRESSAÂ® (gefitinib)TAGRISSOÂ® (osimertinib)TARCEVAÂ® (erlotinib)Prostate cancer BRCA1, BRCA2, and ATM alterations LYNPARZAÂ® (olaparib) BRCA1, BRCA2 alterations RUBRACAÂ® (rucaparib)Ovarian Cancer BRCA1, BRCA2 alterations RUBRACAÂ® (rucaparib)Breast Cancer PIK3CA mutations C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y PIQRAYÂ® (alpelisib)Additionally, FoundationOneÂ® Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.A negative result from a plasma specimen does not mean that the patients tumor is negative for genomic findings. Patients who are negative for the mutations listed in Table 1 should be reflexed to routine biopsy and their tumor mutation status confirmed using an FDA-approved tumor tissue test, if feasible.Genomic findings other than those listed in Table 1 of the intended use statement are not prescriptive or conclusive for labeled use of any specific therapeutic product. FoundationOneÂ® Liquid CDx is a single-site assay performed at Foundation Medicine, Inc. in Cambridge, MA.|44|1
136|P190032|null|FoundationOne Liquid CDx (F1 Liquid CDx)|next generation sequencing oncology panel, somatic or germline variant detection system|2019-12-26 00:00:00|2020-08-26 00:00:00|false|true|Approval for the FoundationOneÂ® Liquid CDx. The device is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions, insertions and deletions (indels) in 311 genes, including rearrangements and copy number losses only in BRCA1 and BRCA2. FoundationOneÂ® Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOneÂ® Liquid CDx cfDNA blood collection tubes included in the FoundationOneÂ® Liquid CDx Blood Sample Collection Kit. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, FoundationOneÂ® Liquid CDx is intended to provide tumor mutation profiling for substitutions and indels to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Table 1: Companion diagnostic indicationsTumor Type Biomarker(s) Detected TherapyNon-small cell lung cancer (NSCLC) EGFR exon 19 deletions andEGFR exon 21 L858R alteration IRESSAÂ® (gefitinib)TAGRISSOÂ® (osimertinib)TARCEVAÂ® (erlotinib)Prostate cancer BRCA1, BRCA2 alterations RUBRACAÂ® (rucaparib)A negative result from a plasma specimen does not mean that the patientâ€™s tumor is negative for genomic findings. Patients who are negative for the mutations listed in Table 1 should be reflexed to routine biopsy and their tumor mutation status confirmed using an FDA-approved tumor tissue test, if feasible.Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. FoundationOneÂ® Liquid CDx is a single-site assay performed at Foundation Medicine, Inc. in Cambridge, MA.|44|1
137|P210001|S001|VENTANA MMR RxDx Panel|immunohistochemistry test, dna mismatch repair (mmr) protein assay|2021-08-18 00:00:00|2022-03-21 00:00:00|false|true|Approval for the Ventana MMR RxDx Panel as a CDx for identifying patients with solid tumors with dMMR status who may benefit from treatment with KEYTRUDA.|45|1
138|P200019|null|VENTANA MMR RxDx Panel|immunohistochemistry test, dna mismatch repair (mmr) protein assay|2020-03-16 00:00:00|2021-04-22 00:00:00|false|true|Approval for the Ventana MMR RxDx Pavel as a CDx for identifying patients with endometrial cancer with dMMR status who may benefit from treatment with Jemperli.|45|1
139|P210001|null|VENTANA MMR RxDx Panel|immunohistochemistry test, dna mismatch repair (mmr) protein assay|2021-01-22 00:00:00|2021-08-17 00:00:00|false|true|Approval for the Ventana MMR RxDx Panel as a CDx for identifying patients with solid tumors with dMMR status who may benefit from treatment with JEMPERLI.|45|1
140|P200011|null|ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA)|next generation sequencing oncology panel, somatic or germline variant detection system|2020-02-18 00:00:00|2021-07-30 00:00:00|false|true|Approval of the ONCO/RevealTM Dx Lung and Colon Cancer Assay (O/RDx-LCCA). The device is a qualitative next generation sequencing based in vitro diagnostic test that uses amplicon-based target enrichment technology for detection of single nucleotide variants (SNVs) and deletions in 2 genes from DNA isolated from formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients with NSCLC or CRC who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. The O/RDx-LCCA is intended to be used on the Illumina MiSeqDxÂ® instrument.Table 1. List of somatic variants for therapeutic useIndication Gene Variant Targeted therapyColorectal Cancer (CRC) KRAS KRAS wild-type (absence of mutations in codons 12 and 13) ERBITUXÂ® (cetuximab), orVECTIBIXÂ® (panitumumab)Non-Small Cell Lung Cancer(NSCLC) EGFR Exon 19 Deletions and Exon 21 L858R Substitution Mutations EGFR Tyrosine Kinase Inhibitors approved by FDA**For the most current information about the therapeutic products in this group, go to: https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htm |46|1
141|P160046|S010|VENTANA PD-L1 (SP263) Assay|immunohistochemistry assay, antibody, programmed death-ligand 1|2021-06-14 00:00:00|2021-10-15 00:00:00|false|true|Approval for the VENTANA PD-L1 (SP263) Assay as a CDx for identifying patients with NSCLC tumors with PD-L1 status of >= 1% TC who may benefit from treatment with TECENTRIQ.|47|1
142|P160046|null|VENTANA PD-L1 (SP263) ASSAY|immunohistochemistry assay, antibody, programmed death-ligand 1|2016-10-20 00:00:00|2017-05-01 00:00:00|false|true|Approval for the VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit on a VENTANA BenchMark ULTRA instrument.PD-L1 status is determined by the percentage of tumor cells with any membrane staining above background or by the percentage of tumor-associated immune cells with staining (IC+) at any intensity above background. The percent of tumor area occupied by any tumor-associated immune cells (Immune Cells Present, ICP) is used to determine IC+, which is the percent area of ICP exhibiting PD-L1 positive immune cell staining. PD-L1 status is considered High if any of the following are met:1) >= 25% of tumor cells exhibit membrane staining; or,2) ICP > 1% and IC+ ? 25%; or,3) ICP = 1% and IC+ = 100%.PD-L1 High status as determined by VENTANA PD-L1 (SP263) Assay was associated with increased objective response rate (ORR) in a single arm study of IMFINZI (durvalumab).|47|1
143|P210026|null|Ki-67 IHC pharmDx|immunohistochemistry assay, antibody, ki-67|2021-06-30 00:00:00|2021-10-12 00:00:00|false|true|Approval of Ki-67 IHC MIB-1 pharmDx (Dako Omnis)For In Vitro Diagnostic Use.Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is a qualitative immunohistochemical (IHC) assay using monoclonal mouse anti-Ki-67, Clone MIB-1, intended for use in the detection of Ki-67 protein in formalin-fixed, paraffin-embedded (FFPE) breast carcinoma tissue using the EnVision FLEX visualization system on Dako Omnis.Ki-67 protein expression in breast carcinoma is determined by using the Ki-67 pharmDx Score, which is the overall percentage of viable tumor cells in the invasive cancer component showing Ki-67 nuclear staining. The specimen should be considered to have Ki-67 expression if Ki-67 pharmDx Score is ? 20.Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is indicated as an aid in identifying patients with early breast cancer at high risk of disease recurrence for whom adjuvant treatment with VerzenioÂ® (abemaciclib) in combination with endocrine therapy is being considered. |48|1
144|K182218|null|FerriSmart Analysis System|null|2018-08-15 00:00:00|2018-11-30 00:00:00|false|true|null|49|4
145|DEN200059|null|POMC/PCSK1/LEPR CDx Panel|null|2020-09-18 00:00:00|2022-01-21 00:00:00|false|true|null|50|2
146|P050040|null|SPOT-LIGHT HER2 CISH KIT|chromogenic in situ hybridization, nucleic acid amplification, her2/neu gene, breast cancer|2011-03-01 00:00:00|2011-04-29 00:00:00|false|true|APPROVAL FOR SPOT-LIGHT HER2 CISH KIT. THIS DEVICE IS INDICATED FOR: THE SPOT-LIGHT HER2 CISH KIT IS INTENDED TO QUANTITATIVELY DETERMINE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) BREAST CARCINOMA TISSUE SECTIONS USING CHROMOGENIC IN SITU HYBRIDIZATION (CISH) AND BRIGHTFIELD MICROSCOPY. THIS TEST SHOULD BE PERFORMED IN A HISTOPATHOLOGY LABORATORY. THE SPOT-LIGHT HER2 CISH KIT IS INDICATED AS AN AID IN THE ASSESSMENT OF PATIENTS FOR WHOM HERCEPTIN (TRASTUZUMAB) TREATMENT IS BEING CONSIDERED. THE ASSAY RESULTS ARE INTENDED FOR USE AS AN ADJUNCT TO THE CLINICOPATHOLOGICAL INFORMATION CURRENTLY BEING USED AS PART OF THE MANAGEMENT OF BREAST CANCER PATIENTS. INTERPRETATION OF TEST RESULTS MUST BE MADE WITHIN THE CONTEXT OF THE PATIENT'S CLINICAL HISTORY BY A QUALIFIED PATHOLOGIST.|26|1
